



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

2022년 2월
석사학위논문

**Chondrocyte oxiaoptophagy
mediated by $7\alpha,25$ -DHC-EBI2 axis
in IL-1 β -induced arthritis**

조선대학교 대학원

글로벌바이오융합학과

서 정 연

Chondrocyte oxiaoptophagy mediated by $7\alpha,25$ -DHC-EBI2 axis in IL-1 β -induced arthritis

관절염에서 $7\alpha,25$ -DHC-EBI2 경로로 매개되는
연골세포의 oxiaoptophagy

2022년 2월 25일

조선대학교 대학원

글로벌바이오융합학과

서 정 연

**Chondrocyte oxiaapoptophagy
mediated by $7\alpha,25$ -DHC-EBI2 axis
in IL-1 β -induced arthritis**

지도교수 전 홍 성

이 논문을 이학 석사학위신청 논문으로 제출함.

2021년 10월

조선대학교 대학원

글로벌바이오융합학과

서 정 연

서정연의 석사학위논문을 인준함

위원장 조선대학교 교수 김도경 (인)

위원 조선대학교 교수 김재성 (인)

위원 조선대학교 교수 전홍성 (인)

2021년 12월

조선대학교 대학원

CONTENTS

LIST OF TABLES	iii
LIST OF FIGURES	iv
LIST OF ABBREVIATIONS	v
국 문 초 록	vii
I . INTRODUCTION	1
II . MATERIALS AND METHODS	4
II-1. Chemicals	4
II-2. Isolation and culture of primary rat chondrocytes	4
II-3. <i>Ex vivo</i> organ culture of rat articular cartilage tissues	5
II-4. Safranin-O & Fast green staining	5
II-5. Quantitative polymerase chain reaction and quantitative real-time PCR	5
II-6. Immunoblotting	6
II-7. Gelatin zymography	7
II-8. Measurement of prostaglandin E ₂	7
II-9. Measurement of nitric oxide	7
II-10. Cell viability assay	8
II-11. Hematoxylin & Eosin staining	8
II-12. Cell survival assay	8
II-13. Nuclear staining	9
II-14. Immunocytochemistry	9
II-15. Immunohistochemistry	9
II-16. Caspase-3/-7 activity assay	10
II-17. Measurement of 25-hydroxycholesterol	10
II-18. ROS staining	11
II-19. Statistical analysis	11

III. RESULTS	15
III-1. IL-1 β induces the progressive degeneration of articular cartilage through the acceleration of proteoglycan loss and the activation of cartilage-degrading enzymes	15
III-2. Inflammatory mediators associated with arthritis risk factors increase in the chondrocytes treated with IL-1 β	18
III-3. IL-1 β induces apoptotic cell death via the cascade activation of caspases in chondrocytes	20
III-4. IL-1 β -induced chondrocyte death is involved with autophagy	23
III-5. IL-1 β induces the synthesis of 25-HC and its downstream oxysterol 7 α ,25-DHC in chondrocytes	25
III-6. 25-HC induces the progressive degeneration of articular cartilage via chondrocyte oxiaoptophagy	27
III-7. 7 α ,25-DHC accelerates the progressive degeneration of articular cartilage via chondrocyte oxiaoptophagy	30
III-8. NIBR189 counteracts 7 α ,25-DHC-induced catabolic effects	33
III-9. NIBR189 counteracts IL-1 β -induced arthritis through the inhibition of chondrocyte oxiaoptophagy	36
IV. DISCUSSION	46
VI. REFERENCES	53
ABSTRACT	60

LIST OF TABLES

Table 1. PCR primer sequences used in this study	12
Table 2. Real-Time PCR primer sequences used in this study	13
Table 3. Immunoblotting antibodies used in this study	14

LIST OF FIGURES

Fig. 1. IL-1 β induces the progressive degeneration of articular cartilage via the acceleration of proteoglycan depletion and the suppression of extracellular matrix synthesis.	16
Fig. 2. IL-1 β induces progressive degeneration of articular cartilage through the activation and expression of cartilage-degrading enzymes.	17
Fig. 3. IL-1 β upregulates the inflammatory mediators and acts as a pathophysiological factor in arthritis.	19
Fig. 4. IL-1 β induces the apoptosis of chondrocytes through the cascade activation of caspases.	21
Fig. 5. IL-1 β -induced chondrocytes death is involved with autophagy	24
Fig. 6. IL-1 β upregulates the production of 25-HC and its downstream oxysterol 7 α ,25-DHC through the expression of the CH25H-CYP7B1 axis in primary rat chondrocytes	26
Fig. 7. 25-HC induces the progressive degeneration of articular cartilage through chondrocyte death involving oxiaapoptophagy, which is accompanied by apoptotic cell death, oxidative stress, and autophagy	28
Fig. 8. 7 α ,25-DHC induces the progressive degeneration of articular cartilage through chondrocyte oxiaapoptophagy	31
Fig. 9. NIBR189 counteracts 7 α ,25-DHC-induced catabolic effects	34
Fig. 10. NIBR189 counteracts IL-1 β -induced catabolic effects	39
Fig. 11. NIBR189 suppresses the expression and activation of cartilage degrading enzymes in the primary rat chondrocytes treated with IL-1 β	40
Fig. 12. NIBR189 suppresses the expression and production of inflammatory mediators in the primary rat chondrocytes treated with IL-1 β	41
Fig. 13. NIBR189 suppresses IL-1 β -induced chondrocytes apoptosis	43
Fig. 14. NIBR189 suppresses IL-1 β -induced autophagy in primary rat chondrocytes	45
Fig. 15. Schematic diagram of chondrocyte oxiaapoptophagy regulated by 25-HC-7 α ,25-DHC-EBI2 axis in arthritis	52

LIST OF ABBREVIATIONS

25-HC	25-hydroxycholesterol
7 α ,25-DHC	7 α ,25-dihydroxycholesterol
ANOVA	Analysis of variance
Bcl-2	B-cell lymphoma 2
Bcl-xL	B-cell lymphoma extra-large
BSA	Bovine serum albumin
CH25H	Cholesterol-25-hydroxylase
Col II	Type II collagen
COX-2	Cyclooxygenase-2
CYP	Cytochrome P450
CYP7B1	Cholesterol by cytochrome P450 family 7 subfamily B member 1
DAPI	4',6-Diamidino-2-phenylindole dihydrochloride
DMEM/F-12	Dulbecco's modified eagls's medium/nutrient mixture F-12
DMSO	Dimethyl sulfoxide
EBI2	Epstein-Barr virus-induced G-protein-coupled receptor 2
ECM	Extracellular matrix
EDTA	Ethylenediaminetetraacetic acid
FBS	Fetal bovine serum
GPx	increase glutathione peroxidase
H&E	Hematoxylin & eosin
H ₂ DCFDA	2',7'-Dichlorodihydrofluorescein diacetate
IACUC	Institutional Animal Care and Use Committee
ICC	Immunocytochemistry
IHC	Immunohistochemistry
IL-1 β	Interleukin-1 β
iNOS	inducible nitric oxide synthase
LC3	Microtubule-associated proteins 1A/1B light chain 3B
MMP	Matrix metalloproteinase

MTT	Dimethyl thiazolyl diphenyl tetrazolium salt
NO	Nitric oxide
OA	Osteoarthritis
PARP	Poly ADP-ribose polymerase
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PGE ₂	Prostaglandin E ₂
PVDF	Polyvinylidene fluoride
qPCR	Quantitative polymerase chain reaction
qRT-PCR	Quantitative real-time PCR
RA	Rheumatoid arthritis
ROR α	Retinoic acid-related orphan receptor α
ROS	Reactive oxygen species
RT	Room temperature
S.D.	Standard deviation
SOD	Superoxide dismutase
SPSS	Statistical Package for the Social Sciences
SREBP-2	Sterol regulatory element binding protein 2
TBS-T	Tris buffered saline with Tween 20
$\Delta\psi_m$	Mitochondrial membrane potential

국 문 초 록

관절염에서 $7\alpha,25$ -DHC-EBI2 경로로 매개되는 연골세포의 oxiaoptophagy

서 정 연

지도교수 : 전홍성
글로벌바이오융합학과
조선대학교 대학원

$7\alpha,25$ -dihydroxycholesterol($7\alpha,25$ -DHC)은 염증 조건 하에서 cholesterol by cytochrome P450 family 7 subfamily B member 1(CYP7B1)이라는 효소에 의해 25-hydroxycholesterol(25-HC)로부터 합성되는 옥시스테롤이며, 이는 다양한 유형의 세포에서 세포사멸과 관련되어 있다. 본 연구에서는 interleukin- 1β (IL- 1β)와 $7\alpha,25$ -DHC가 유도하는 연골세포 oxiaoptophagy에서 $7\alpha,25$ -DHC 수용체 Epstein-Barr virus-induced G-protein-coupled receptor 2(EBI2)의 길항작용과 그 기전을 분석하였다.

IL- 1β 는 흰쥐 관절 연골에서 세포외 기질의 주요 구성요소인 aggrecan과 Type II collagen의 발현을 감소시켜 연골세포의 점진적인 퇴행을 증가시켰으며 세포에서 관절염의 주요 인자인 matrix metalloproteinase(MMP)-1, -3, -13과 염증 매개체인 inducible nitric oxide synthase, cyclooxygenase-2, 산화질소 및 prostaglandin E_2 의 발현을 증가시켰다. 또한, 흰쥐 관절 연골세포에서 IL- 1β 는 외인성 세포사멸 인자인 caspase-8과 내인성 세포사멸 인자인 caspase-9를 활성화시켜 caspase-3과 Poly ADP-ribose polymerase의 활성화를 유도하였으며, 이와 더불어 자가포식작용 바이오마커인 beclin-1과 microtubule-associated proteins 1A/1B light chain 3B의 발현 증가를 유도하여 연골세포의 생존력을 감소시켰다. 이러한 결과는 흰쥐 연골세포에서 IL- 1β 가 산화적 스트레스를 동반한 연속적인 caspase 활성화에 의한 세포사멸과 자가포식작용을 동시에 유도할 수 있음을 시사한다. 또한 IL- 1β 에 의한 연골세포 사멸 시 25-HC와 $7\alpha,25$ -DHC 등과 같은 옥시스테롤 합성이 동반됨을 제시하고 있

다. 이에 따라 본 연구에서는 염증 상태에서 콜레스테롤로부터 합성되는 25-HC와 그의 하위 옥시스테롤인 7 α ,25-DHC가 흰쥐 관절연골의 프로테오글리칸 소실의 가속화와 더불어 산화적 스트레스와 자가포식작용을 동반한 세포사멸인 oxiaoptophagy를 통해 관절연골 퇴행성을 유도한다는 것을 입증하였다. 반면 7 α ,25-DHC 수용체 EBI2 길항제인 NIBR189는 7 α ,25-DHC에 의해 유도되는 연골세포 산화작용, 세포사멸 및 자가포식작용을 억제하였다. NIBR189는 7 α ,25-DHC에 의해 증가된 pro-apoptotic factor 및 autophagy 바이오마커의 발현 억제를 통하여 연골세포사멸을 감소시켰으며, 생체 외 장기 배양 관절 연골에서 7 α ,25-DHC에 의해 매개되는 프로테오글리칸 소실을 억제하였다. 이러한 결과는 7 α ,25-DHC 수용체 억제 시 IL-1 β 에 의해 유도되는 관절연골퇴행성이 지연 또는 예방될 수 있음을 제시한다. 본 연구에서는 NIBR189는 흰쥐 관절연골에서 IL-1 β 가 유도하는 프로테오글리칸 소실 및 세포외 기질 성분 감소를 억제하였으며, 연골세포에서 IL-1 β 에 의한 연골 분해 효소 및 염증 매개체의 발현증가를 억제하였다. 또한 NIBR189는 연골세포에서 IL-1 β 로 유도된 세포독성과 세포사멸 및 자가포식작용을 억제하였다.

본 연구의 결과는 7 α ,25-DHC 수용체 EBI2의 길항작용이 IL-1 β 로 유도되는 연골세포 oxiaoptophagy를 억제시킬 수 있음을 시사한다. 따라서 본 연구의 결과로, EBI2 억제를 이용한 관절염 예방 및 치료전략의 방향을 제시할 수 있을 것으로 사료된다.

I . INTRODUCTION

Synovial joints located between bones permit the movement and mobility of the body through abduction, adduction, extension, and flexion of the body in mammals [1]. The joint is composed of two bones, articular cartilage, and synovial fluid, and is an organ that enables mobility for the human body [2].

Articular cartilage is a smooth white tissue that wraps around the ends of bones that join to form joints, and acts as a cushion that enables mobility by alleviating friction and distributing the load on the upper body [3]. Articular cartilage is mainly composed of water and chondrocytes, which are special cells with an extracellular matrix (ECM) composed of type II collagen (COL II) and aggrecan, which is a component of proteoglycan [4].

Chondrocytes maintain homeostasis, and an imbalance can lead to the degeneration of articular cartilage, inducing arthritis such as osteoarthritis (OA) and rheumatoid arthritis (RA) [5]. Although the pathophysiological risk of arthritis is multifactorial, including genetic predisposition, aging, obesity, traumatic joint injury, and joint misalignment, and is the closely related to chronic oxidative stress and inflammation in the synovial joint, its pathophysiological etiology is largely unknown [6]. Articular cartilage cell death is pathologically related to arthritis [7]. Therefore, although the survival of articular cartilage cells is a very important, and the relationship between apoptosis and inflammatory response has been discussed, the pathological mechanism of articular cartilage cell death has not been elucidated [8].

Arthritis is a chronic joint disease in which the articular cartilage of the synovial joint degenerates, leading to inflammation and pain making it difficult to keep the body moving and restricting activity [9]. Also, arthritis is a chronic joint disease in which the articular cartilage of the synovial joint degenerates, causing pain. Arthritis is caused by multifactorial factors such as aging, obesity, joint deformity, traumatic joint damage, and genetic predisposition, which is closely related to chronic oxidative stress and inflammation in the synovial joint within the synovial joint, but the exact mechanism has not been revealed [10].

Recently, a pathological association of chronic low-grade inflammation, caused by metabolic diseases and aging, with arthritis has been determined [11]. Cholesterol is an essential component of cells, and oxysterol, a cholesterol metabolite, is produced by auto-oxidation, an enzymatic reaction [12]. High levels of oxysterol are produced by metabolic diseases, such as Huntington's disease, Parkinson's disease, Alzheimer's disease, atherosclerosis, and carcinogenesis in various types of cancers, and chronic low-grade inflammation increases with aging [13-15].

In addition, oxysterol has recently been shown to play an important role in various biological processes, such as cholesterol homeostasis regulation, lipid metabolism regulation, autophagy, and apoptosis as an oxidative metabolite produced by oxidase or pro-oxygen in the cholesterol metabolism process [16]. A recent study reported that oxysterol associated with cholesterol homeostasis significantly increases in patients with arthritis [16], indicating, the relationship between oxysterol and apoptosis [17]. In addition, oxysterols overexpress reactive oxygen species (ROS) and increase glutathione peroxidase (GPx) and superoxide dismutase (SOD) [18]. Through this, the loss of mitochondrial membrane potential ($\Delta\psi_m$), activation of caspase-3, degradation of poly (ADP-ribose) polymerase (PARP), reduction of B-cell lymphoma 2 (Bcl-2), and nuclei condensation and fragmentation occur, resulting in apoptosis caused by oxidative stress [19]. Autophagy also leads to the formation of large cytoplasmic vacuoles, considered autophagic vacuoles, and the activation of Microtubule-associated protein 1A/1B-light chain 3-I (LC3)- I to LC3- II, which is considered to be an autophagic criterion associated with autophagosome formation [20].

Recent studies have shown that 25-hydroxycholesterol (25-HC), an oxysterol synthesized by cholesterol from cholesterol 25-hydroxylase (CH25H), induces apoptosis in various types of cells, including motor neuron-like cell lines and head and neck squamous cell carcinoma FaDu cells [21,22]. Additionally, P2X7-dependent pyroptosis is induced by 25-HC in human keratinocytes NSC34 [23]. In addition 25-HC acts as an oxysterol to induce chondrocyte apoptosis through the CH25H-CYP7B1-retinoic acid-associated orphan receptor α (ROR α) axis in OA [24].

Oxysterol $7\alpha,25$ -dihydroxycholesterol ($7\alpha,25$ -DHC) is synthesized from cytochrome

P450 Family 7 Subfamily B Member 1 (CYP7B1) from 25-HC under inflammatory conditions, which is associated with apoptosis in various cell types [17]. The $7\alpha,25$ -DHC receptor epstein-Barr virus-induced G-protein-coupled receptor 2 (EBI2) is required for the generation of antibody responses and has been implicated in a variety of inflammatory diseases [25]. Regulatory elements of EBI2 expression are associated with cardiac inflammation, type 1 diabetes, and inflammatory bowel disease [26]. The expression of EBI2, CH25H, $7\alpha,25$ -DHC, and CYP7B1 was found to be highly regulated under many inflammatory diseases [25]. Therefore, aim of this study was to investigate the antagonism of the $7\alpha,25$ -DHC receptor EBI2 and its mechanism in $7\alpha,25$ -DHC-induced chondrocyte oxiapoptophagy. In addition, this study analyzed a novel pathophysiological link between cholesterol metabolism and arthritis based on apoptosis, oxidative stress and oxiapoptophagy, another type of cell death accompanied by autophagy.

II. MATERIALS AND METHODS

II-1. Chemicals

Interleukin-1 β (IL-1 β) was purchased from ProSpec-Protein Specialists (Rehovot, Israel) and was dissolved in distilled water at stock concentration (10 μ g/mL). 25-HC was purchased from Tocris Bioscience (Bristol, United Kingdom) and was dissolved in ethanol at stock concentration (8 mg/mL). 7 α ,25-DHC was purchased from Sigma-Aldrich (St. Louis, MO, USA) and was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at stock concentration (5 mg/mL). NIBR189 was purchased from Sigma-Aldrich and was dissolved in DMSO at stock concentration (50 mM).

II-2. Isolation and culture of primary rat chondrocytes

Primary rat chondrocytes were extracted from articular cartilage of rats (5-day-old; Sprague-Dawley, Damul Science Co., Daejeon, Republic of Korea) knee joints, in accordance with the protocol approved by the Institutional Animal Care and Use Committee (IACUC) of Chosun University, Gwangju, Republic of Korea (CIACUC2020-A0011). Dissected cartilage tissues were washed in antibiotics (100 U/mL penicillin and 100 μ g/mL streptomycin; Welgene, Gyeongsan-si, Gyeongsangbuk-do, Republic of Korea). Subsequently, Trypsin-Ethylenediaminetetraacetic acid (EDTA; Welgene) was treated to leave only cartilage tissue. And then 0.02% collagenase P (Sigma-Aldrich) was treated to isolate chondrocyte. Isolated primary rat chondrocytes were cultured in Dulbecco's Modified Eagle's Medium/Nutrient Mixture F-12 (DMEM/F-12; Welgene) supplemented with 10% fetal bovine serum (FBS; Welgene), antibiotics, and 50 μ g/mL ascorbic acid (Sigma-Aldrich).

II-3. *Ex vivo* organ culture of rat articular cartilage tissues

The articular cartilage tissue was isolated from the knee joint of 5-day-old Sprague-Dawley rats and then cultured in DMEM/F-12 supplemented with 10% FBS. Next, the articular cartilage tissue was treated defined treatment conditions for 14 days. At the end of the culture period, the sample was collected and washed in PBS. To perform histological analysis, the sample was fixed in 4% paraformaldehyde for 72 h.

II-4. Safranin-O & fast green staining

To verify the loss of proteoglycan in articular cartilage, histological analysis using safranin-O & fast green staining was performed. Briefly, the articular cartilage tissue was decalcified in EDTA and embedded in paraffin. sequentially, the prepared paraffin block containing articular cartilage was serially sliced to 6 – 7 μm thickness using microtome (Leica Biosystems, Wetzlar, Hesse, Germany) and placed on slides. To assess proteoglycan loss in the articular cartilage ground substance, safranin-O & fast green (Thermo Fisher Scientific, Waltham, MA, USA) staining was performed. The slide was observed and imaged using Leica DM750 microscope (Leica Microsystems, Heerbrugg, Switzerland).

II-5. Quantitative polymerase chain reaction (qPCR) and quantitative real-time PCR (qRT-PCR)

To investigate the alteration of mRNA induction, qPCR and qRT-PCR were performed. Chondrocytes were treated with defined treatment conditions. Thereafter, total RNA was isolated from the chondrocyte using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The concentrations of the isolated total RNA were measured using a Nanodrop 2000 (ThermoFisher Scientific). To synthesize cDNA, 1 μg RNA was reverse transcription using a

qPCR BIO cDNA Synthesis Kit (PCR Biosystems Ltd., London, UK) according to the manufacturer's instructions. For qRT-PCR, cDNA was amplified using an Eco Real-Time PCR system (Illumine Inc., San Diego, CA, USA). Relative gene expressions were determined using the $\Delta\Delta$ CT method, as detailed by the manufacturer (Illumine Inc). qPCR was performed using 2 x TOP simple DyeMIX-*n*Taq (Enzynomics, Seoul, Republic of Korea) and specific primers on a TaKaRa PCR Thermal Cycler Dice (TaKaRa Bio Inc., Kusatsu, Shiga, Japan). Thereafter, To determine the expression level of the target genes, the PCR product was electrophoresed on an agarose gel. β -actin was used as an internal control, the primer sequences and the used conditions were summarized in Table 1 and Table 2.

II-6. Immunoblotting

Immunoblotting was performed to investigate the alteration of protein expression. Chondrocytes were cultured in a 12-well plate and treated with defined treatment conditions. Thereafter, the total protein was extracted from the chondrocytes using a PRO-PREP (iNtRON Biotechnology, Seongnam-si, Gyeonggi-do, Republic of Korea) included Phosphatase Inhibitor Cocktail III (AG scientific, San Diego, CA, USA), according to the manufacturer's instructions. Protein concentrations were determined using a bicinchoninic acid protein assay (ThermoFisher Scientific). Equal amount of each protein sample was electrophoresed on 10% sodium dodecyl sulfate polyacrylamide gel and subsequently transferred to polyvinylidene fluoride (PVDF) membrane (Millipore, Burlington, MA, USA) at 4°C. Thereafter, the PVDF membrane was blocked using 5% (v/v) bovine serum albumin (BSA; Bioshop, Burlington, Ontario, Canada), prepared in tris buffered saline with Tween 20 (TBS-T; Santa Cruz Biotechnology Inc., Dallas, TX, USA). Sequentially, membranes were incubated with the primary antibodies at 4°C and incubated with the secondary antibodies in TBS-T containing 5% (v/v) BSA. The immunoreactive band was visualized using the ECL System (Amersham Biosciences, Piscataway, NJ, USA), exposed on radiographic film or MicroChemi 4.2 (Dong-Il Shimadzu Corp., Seoul, Republic of Korea). The antibodies and the conditions used are summarized in Table 3.

II-7. Gelatin zymography

To assess the activation of matrix metalloproteinases (MMPs) in primary rat chondrocytes, gelatin zymography was performed. Briefly, primary rat chondrocytes were treated with defined treatment conditions. Thereafter, an equal volume of conditioned medium was electrophoresed on a 8% polyacrylamide gel containing co-polymerized 0.2% (1 mg/mL) porcine skin gelatin. After electrophoresis, the gel was incubated in zymogram renaturing buffer (50 mM Tris-HCl [pH 7.6], 10 mM CaCl₂, 50 mM NaCl, and 0.05% Brij-35) at 37°C for 72 h. After renaturation of MMPs, the gel was stained by 0.1% Coomassie Brilliant Blue R250. Gelatinolytic band was revealed as clear bands on a background uniformly stained light blue and then imaged using a digital camera (Canon, Ota, Tokyo, Japan).

II-8. Measurement of prostaglandin E₂ (PGE₂)

To measure PGE₂, primary chondrocytes were seeded at 1×10^6 cells/mL in a 12 well culture plate. Chondrocytes were treated with defined treatment conditions. The production of PGE₂ was measured using a PGE₂ Parameter Assay Kit (R&D SYSTEMS, Minneapolis, MN, USA), Diluent RD5-56 calibrator added to the remaining standard and conditioned wells. And 50 μ L of primary antibody solution was reacted to each well. The plate was covered tightly with sealant and incubated for 1 h. Then, 50 μ L of PGE₂ Conjugate was added to each well and incubated for 2 h. Subsequently, the well was rinsed and added substrate solution to each well, then incubate for 30 min in a dark condition. Finally, 100 μ L of stop solution was reacted to each well. Absorbance was measured at 450 nm using a spectrophotometer (Epoch microplate Spectrophotometer; BioTek, Winooski, VT, USA).

II-9. Measurement of nitric oxide (NO)

Primary rat chondrocytes were treated with defined treatment conditions. Thereafter,

the conditioned medium was reacted with each equal amount of sulfanilamide (Duksan Company, Ansan, Gyeonggi-do, Republic of Korea) containing 5% (v/v) phosphoric acid (Duksan company) and *N*-1-naphthylethylenediamine dihydrochloride (Sigma-Aldrich). Absorbance was measured at 540 nm wavelength using a spectrophotometer.

II-10. Cell viability assay

Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Alfa Aesar, Haverhill, MA, USA). Chondrocytes (1×10^6 cells/mL) were cultured in 48-well culture plates, and then treated with defined treatment conditions. Following addition MTT solution, the chondrocytes were further incubated for 4 h. After incubation, the MTT crystal that formed was suspended completely in DMSO and the absorbance was read at 570 nm using a spectrometer.

II-11. Hematoxylin & Eosin (H&E) staining

H&E staining was performed to observe the morphological alteration of rat primary chondrocytes. Chondrocytes (1×10^6 cells/mL) were cultured in 8-well chamber slide (Nunc Lab-Tek II Chamber Slide system; Sigma-Aldrich) and treated with defined treatment conditions. Subsequently, cells were fixed in 4% paraformaldehyde for 30 min at 4°C and washed with phosphate buffered saline (PBS; Sigma-Aldrich). After staining with Haematoxylin (YD-Diagnostics, Yongin-si, Gyeonggi-do, Republic of Korea) and Eosin (Junsei Chemical Co., Tokyo, Japan), cells were observed and imaged using Leica DM750 microscope.

II-12. Cell survival assay

To measure the survival of chondrocyte treated with IL-1 β , cell survival assay was performed using a Live/Dead Viability/Cytotoxicity kit (Invitrogen), which consists of

green calcein AM for labeling live cells and ethidium homodimer-1 for labeling dead cells. Chondrocytes were cultured in 8-well chamber slides (Nunc Lab-Tek II Chamber Slide system; Sigma-Aldrich), and then treated with defined treatment conditions. Thereafter, the stained cell was imaged using a fluorescence microscope.

II-13. Nuclear staining

To detection the condensed nucleus of the cell, 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) staining was performed. Chondrocytes were cultured in 8-well chamber slide and treated with defined treatment conditions. Thereafter, the cells were rinsed three times with PBS and stained with DAPI. Nuclear condensations were observed and imaged using a fluorescence microscope.

II-14. Immunocytochemistry (ICC)

ICC was performed to observe the alteration of target protein expression in chondrocyte. Chondrocytes (1×10^6 cells/mL) were cultured in 8-well chamber slide, then cells were treated with defined treatment condition for 24 h. Thereafter, the cells were post-fixed in 4% paraformaldehyde for 10 min and reacted in endogenous peroxidase block 10 min. Slides were incubated using a Vectastain[®] ABC Kit (Vector Laboratories, Burlingame, CA, USA) at 4°C with primary antibody (caspase-3). Beclin-1 antibody was treated overnight, and then slides were incubated with peroxidase-conjugated goat anti-mouse antibody for 1 h at room temperature (RT). Slides were subsequently counterstained using hematoxylin. Subsequently, slides were transferred to the mounting reagent and examined by microscopy.

II-15. Immunohistochemistry (IHC)

IHC was performed to observe the alteration of target protein expression in *ex vivo* organ-cultured articular cartilage, using Vectastain[®] ABC Kit. *Ex vivo*

organ-cultured articular cartilage was post-fixed in 4% paraformaldehyde for 7 days and dehydrated in a series of ethanol solutions (70, 80, 90, and 100%; 2 h per step). sequentially, samples were submerged in xylene twice for 2 h and in paraffin twice for 2 h. Embedded tissue block was prepared and cutted using a microtome. The 7- μ m-thick sections were placed on glass slides. The section was deparaffinized using two changes of xylene for 3 min, rehydrated with two washes each of 100, 90, 80, and 70% ethanol for 3 min. Rehydrated section was rinsed with tap water for 3 min. The sections were incubated with caspase-3, beclin-1 antibody at 4°C overnight and then incubated with peroxidase-conjugated goat anti-mouse antibody for 1 h at RT. The section was subsequently counterstained using hematoxylin, transferred to the mounting reagent, and examined by microscopy.

II-16. Caspase-3/-7 activity assay

Chondrocytes were cultured in 8-well chamber slide, and treated with defined treatment conditions. Thereafter, the activity of caspase-3/-7 was examined using the cell permeable fluorogenic substrate PhiPhiLux-G₁D₂ (OncoImmunin Inc., Gaithersburg, MD, USA). After cell staining, caspase-3/-7 activity was imaged using fluorescence microscopy.

II-17. Measurement of 25-HC

To measure 25-HC, chondrocytes were seeded at 1×10^6 cells/mL in a 12 well culture plate. Chondrocytes were treated with defined treatment conditions. The production of 25-HC was measured using a Rat 25-Hydroxycholesterol ELISA Kit (My BioSource, San Diego, CA, USA). 50 μ L of Sample Diluent was added to the remaining standard and conditioned wells. And 50 μ L of standard solution was added to each well, 50 μ L of cell pellet in PBS was added to each well. 100 μ L of horseradish peroxidase (HRP)-conjugate reagent was added to each well, covered the plate tightly with sealant in incubated for 1 h at 37°C. And then samples were

rinsed 1X washing solution to each well, four repetitions. Subsequently, 50 μ L chromogen solution was added to each well, incubated for 15 min in a dark place at 37°C. Finally, 50 μ L of stop solution was reacted to each well. Absorbance was measured at 450 nm using a spectrophotometer.

II-18. ROS staining

2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA; Sigma-Aldrich) staining was performed to investigate the production of ROS. Chondrocytes were cultured in 8-well chamber slide and were treated with defined treatment conditions. Thereafter, the cells were rinsed three times with PBS and stained with H₂DCFDA. ROS was observed and imaged using a fluorescence microscope.

II-19. Statistical analysis

All experimental were performed at least 3 times, and all experimental data was expressed as mean \pm standard deviation (S.D.). The statistical significance was analyzed by using Student's *t*-test for two groups and one way analysis of variance (ANOVA) for multi-group comparisons. All statistical analyses was performed using Statistical Package for the Social Sciences (SPSS) software package version 22.0 (IBM, Armonk, NY, USA). A *p*-value < 0.05 was considered statistically significant.

Table 1. qPCR primer sequences used in this study

Gene	Primer sequences	NCBI gene no.
<i>aggrecan</i>	Forward : 5'-CAGAGGAACACACCGAAAGT-3' Reverse : 5'-GCACACTGGCTCCATCTATT-3'	NM_022190.1
<i>ch25h</i>	Forward : 5'-CCCTTCTTCCCAGTCATCTTT-3' Reverse : 5'-TCCCAGACGCTCATGTATTG-3'	NM_001025415.1
<i>col II</i>	Forward : 5'-GGTCCTGGCAGTCGACAT-3' Reverse : 5'-GTGCGAGCGGGATTCTT-3'	NM_012929.1
<i>cox-2</i>	Forward : 5'-CCCTTCCTCCTGTGGCTGAT-3' Reverse : 5'-CCCAGGTCCCTCGTTCTGAT-3'	NM_017232.3
<i>cyp7b1</i>	Forward : 5'-CGGGCATGAAGAGTTTGAAATAG-3' Reverse : 5'-AGACTTCTGGGTCATTGTGTATC-3'	NM_019138.1
<i>inos</i>	Forward : 5'-GCATCGGCAGGATTCAGTGG-3' Reverse : 5'-TAGCCAGCGTACCGGATGAG-3'	NM_012611.3
<i>mmp-1</i>	Forward : CAACGCAGATTTAGCCTCCGA Reverse : GAGATGCCCAGGACCACAGT	NM_001134530.1
<i>mmp-3</i>	Forward : 5'-TCCTACCCATTGCATGGCAGTGAA-3' Reverse : 5'-GCATGAGCCAAGACCATTCCAGG-3'	NM_133523.2
<i>mmp-13</i>	Forward : 5'-GGCAAAGCCATTTTCATGCTCCCA-3' Reverse : 5'-AGACAGCATCTACTTTGTCGCCA-3'	NM_133530.1
<i>β-actin</i>	Forward : 5'-CGATAAAGGAAGGCTGGAAGAG-3' Reverse : 5'-GTGCCCATCTATGAGGGTTATG-3'	NM_019212.2

Table 2. qRT-PCR primer sequences used in this study

Gene	Primer sequences	NCBI gene no.
<i>aggrecan</i>	Forward : 5'-CCCCAAATCCCTCATACTCAG-3' Reverse : 5'-CTGTTTCTCCTGACCCTTCTG-3'	NM_032893390.1
<i>ch25h</i>	Forward : 5'-CACTCACCATCCTCGTCTTTC-3' Reverse : 5'-GGAAAGTCGTAACCTGAGTGG-3'	NM_001025415.1
<i>col II</i>	Forward : 5'-AGCACATCTGGTTTGGAGAG-3' Reverse : 5'-CAGTGGTAGGTGATGTTCTGG-3'	NM_012929.1
<i>cox-2</i>	Forward : 5'-CAACCCATGTCAAACCGTG-3' Reverse : 5'-TTGTCAGAACTCAGGCGTAG-3'	NM_017232.3
<i>cyp7b1</i>	Forward : 5'-AATTGTTTCAGGAGAGGCAGG-3' Reverse : 5'-CATAGCTGGAATGGTGTTC-3'	NM_019138.1
<i>inos</i>	Forward : 5'-CGGTGTTCTTTGCTTCTGTG-3' Reverse : 5'-TGAAGGCGTAGCTGAACAAG-3'	NM_012611.3
<i>mmp-1</i>	Forward : 5'-CAACGCAGATTTAGCCTCCGA-3' Reverse : 5'-GAGATGCCCAGGACCACAGT-3'	NM_001134530.1
<i>mmp-3</i>	Forward : 5'-GACCCTGAGACCTTACCAATG-3' Reverse : 5'-AAAGAACAAGACTTCTCCCCG-3'	NM_133523.3
<i>mmp-13</i>	Forward : 5'-GATGAAGACCCCAACCCTAAG-3' Reverse : 5'-GGAGACTAGTAATGGCATCAAGG-3'	NM_133530.1
<i>β-actin</i>	Forward : 5'-ATGGGTGTGAATGAGAAGGAC-3' Reverse : 5'-GTCATTAGCCCTTCCACGATC-3'	NM_023964.1

Table 3. Immunoblot antibodies used in this study

Antibodies	Molecular weight (kDa)	Dilution Concentration	Secondary Antibody
β-actin	43	1 : 5000	Mouse
Beclin-1	60	1 : 2000	Mouse
CH25H	36	1 : 2500	Mouse
Cleaved-caspase-3	17	1 : 2000	Rabbit
Cleaved-caspase-8	41	1 : 2500	Rabbit
Cleaved-caspase-9	37, 39	1 : 2500	Rabbit
COX-2	74	1 : 1500	Rabbit
CYP7B1	48	1 : 2500	Rabbit
iNOS	130	1 : 1000	Rabbit
LC3	16, 18	1 : 2000	Rabbit
MMP-1	46	1 : 2500	Rabbit
MMP-3	57	1 : 2000	Mouse
MMP-13	48	1 : 2000	Mouse
Cleaved-PARP	89	1 : 2000	Rabbit


III. RESULTS

III-1. IL-1 β induces the progressive degeneration of articular cartilage through the acceleration of proteoglycan loss and the activation of cartilage-degrading enzymes

To determine whether IL-1 β accelerates proteoglycan loss, the explant of articular cartilage was dissected from the knee joint of 5-day-old rats were cultured *ex vivo* with 10 and 50 ng/mL IL-1 β for 14 days. Thereafter, the explant was fixed with 4% paraformaldehyde and safranin-O & fast green staining was performed to stain the proteoglycan. As shown in Fig. 1A, proteoglycans were decreased in articular cartilage treated with 10 and 50 ng/mL IL-1 β compared with the untreated controls. Furthermore, IL-1 β significantly suppressed the induction of mRNAs associated with the major components of the ECM such as aggrecan and Col II, in primary rat chondrocytes (Fig. 1B).

Next, to verify IL-1 β -induced catabolic effect such as the expression and activation of cartilage-degrading enzymes, primary rat chondrocytes were cultured with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, qPCR, qRT-PCR, immunoblotting, and gelatin zymography were performed to assess the alteration of cartilage-degrading enzymes. As shown in Fig. 2A - 2C, the expression of MMP-1, -3, and -13 mRNAs was significantly increased in the chondrocytes treated with IL-1 β . As shown in Fig. 2D, the activity of cartilage-degrading enzymes was increased in chondrocytes treated with 10 and 50 ng/mL IL-1 β . These data indicate that IL-1 β induces the progressive degeneration of articular cartilage through an increase in proteoglycan loss, which is mediated by both the activation of cartilage-degrading enzymes and the suppression of ECM components in primary rat chondrocytes.

A.



B.




Fig. 1. IL-1 β induces the progressive degeneration of articular cartilage via the acceleration of proteoglycan depletion and the suppression of ECM synthesis. A, IL-1 β accelerates the proteoglycan loss from articular cartilage dissected from rat knee joint. Explants of articular cartilage tissues were dissected from rat knee joint treated with 10 and 50 ng/mL IL-1 β for 14 days. Thereafter, explants fixed with 4% paraformaldehyde were exposed to safranin-O & fast green staining to stain the proteoglycan. Images were captured using a microscope. B, the synthesis of ECM components, such as aggrecan and col II, was significantly decreased in the primary rat chondrocytes treated with IL-1 β . Primary rat chondrocytes were isolated from the articular cartilage of rat knee joint treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, total RNA was isolated to perform the qRT-PCR after the synthesis of cDNA.




Fig. 2. IL-1 β induces progressive degeneration of articular cartilage through the activation and expression of cartilage-degrading enzymes. Primary rat chondrocytes were treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, total RNA, total protein, and conditioned media were collected for qPCR (A), qRT-PCR (B), and immunoblotting (C) using specific antibodies associated with cartilage-degrading enzymes, such as MMP-1, -3, and -13, and gelatin zymography (D). A & B, the mRNAs encoding *mmp-1*, -3, and -13 were significantly increased by IL-1 β in primary rat chondrocytes. C, the expression of MMP-1, -3, and -13 proteins was significantly upregulated in primary rat chondrocytes treated with IL-1 β . D, the activation of MMPs associated with cartilage-degrading enzymes was increased in the conditioned media collected from primary rat chondrocytes treated with IL-1 β .

III-2. Inflammatory mediators associated with arthritis risk factors increase in the chondrocytes treated with IL-1 β

To determine whether IL-1 β induces inflammatory mediators, an arthritis risk factors, primary rat chondrocytes were cultured with 10 and 50 ng/ml IL-1 β for 24 h. Thereafter, the mRNA and protein level of inflammatory mediators, such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), were assessed. As shown in Fig. 3A - 3C, the mRNA and protein level of iNOS and COX-2 significantly increased after IL-1 β treatment in chondrocytes. The relative production of NO increased by $224.44 \pm 9.45\%$ and $333.38 \pm 5.34\%$ in the chondrocytes treated with 10 and 50 ng/mL IL-1 β , respectively, compared with that in control cells ($100.01 \pm 1.94\%$) (Fig. 3D). The production of PGE₂ significantly increased by $4,242.21 \pm 905.97$ pg/mL and $7,194.30 \pm 1,210.73$ pg/mL in the chondrocytes treated with 10 and 50 ng/mL IL-1 β , respectively, compared with that in the control cells ($1,471.09 \pm 572.78$ pg/mL). These data indicate that IL-1 β upregulates the production of inflammatory mediators, such as iNOS, COX-2, NO, and PGE₂, which act as arthritis risk factors in primary rat chondrocytes.




Fig. 3. IL-1 β upregulates the inflammatory mediators and acts as a pathophysiological factor in arthritis. Primary rat chondrocytes were treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, total RNA and total protein were collected for qPCR (A), qRT-PCR (B), and immunoblotting (C) using specific antibodies associated with inflammatory mediators, NO assay (D), and PGE₂ ELISA (E). A & B, the mRNAs encoding *inos* and *cox-2* were significantly increased by IL-1 β in primary rat chondrocytes. C, expression of iNOS and COX-2 proteins was significantly upregulated in primary rat chondrocytes treated with IL-1 β . D, NO production was significantly increased by IL-1 β in primary rat chondrocytes. E, IL-1 β upregulated the production of PGE₂ in primary rat chondrocytes.

III-3. IL-1 β induces apoptotic cell death via the cascade activation of caspases in chondrocytes

Primary rat chondrocytes were treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, MTT assay, cell live/dead staining, and DAPI staining were performed to verify cell viability, cell survival, and the alteration of chromatin in primary rat chondrocytes, respectively. As shown in Fig. 4A, relative cell viability was measured to be $87.92 \pm 2.22\%$ and $83.05 \pm 1.61\%$ in the chondrocytes treated with 10 and 50 ng/mL IL-1 β , respectively, compared with that of the untreated control ($100.01 \pm 1.68\%$). Moreover, cell live/dead staining showed that the number of living chondrocytes decreased because of IL-1 β in a dose-dependent manner (Fig. 4B upper panel). Furthermore, the results of H&E staining showed that IL-1 β not only decreased the number of chondrocytes in a dose-dependent manner but also increased the altered condensed morphology in chondrocytes (Fig. 4B middle panel). In addition, the result of DAPI staining showed that the number of chondrocytes with condensed chromatin, a typical feature of apoptosis, was increased by IL-1 β in a dose-dependent manner (Fig. 4B lower panel). These results indicate that IL-1 β -induced chondrocyte death is involved in apoptosis.

Hence, to verify whether IL-1 β -induced chondrocyte death is mediated by apoptosis, immunoblotting using caspase-8, -9, -3, and PARP specific antibodies was performed. The expression of pro-apoptotic factors, including cleaved caspase-8, -9, -3, and PARP, significantly increased in primary rat chondrocytes treated with IL-1 β (Fig. 4C). Furthermore, the results of caspase-3/-7 activity assay and ICC using caspase-3 specific antibodies showed that IL-1 β not only upregulated the activity of caspase-3 but also increased the expression of caspase-3 in primary rat chondrocytes (Fig. 4D). Taken together, these data consistently indicate that IL-1 β induces chondrocyte apoptosis through the cascade activation of caspases associated with the death receptor-mediated extrinsic and mitochondria-dependent intrinsic apoptosis pathways in primary rat chondrocytes.





Fig. 4. IL-1 β induces the apoptosis of chondrocytes through the cascade activation of caspases. Primary rat chondrocytes were treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, MTT assay (A), cell live/dead staining (B, upper panel) using ethidium homodimer-1 to stain the dead cells with red fluorescence and green calcein AM to stain live cells with green fluorescence, and DAPI staining (B, lower panel) were performed to investigate the viability, survival, and chromatin condensation of primary

chondrocytes. Total proteins extracted from primary rat chondrocytes treated with IL-1 β were analyzed to verify the expression of caspases including caspase-8, -9, and -3 by immunoblotting (C). In addition, to verify the activation and expression of caspase-3, caspase-3/-7 activity staining (D, left panel) using PhilphiLuxG₁/G₂ substrate, and ICC (D, right panel) with caspase-3 specific antibody was performed in primary rat chondrocytes. A, The viability of primary rat chondrocytes was decreased by IL-1 β in a dose-dependent manner. B, The number of dead cells with condensed chromatin was increased in primary rat chondrocytes treated with IL- β . C, the expression of cleaved caspases-8, -9, and -3 was increased by IL-1 β in primary rat chondrocytes. D, the activity and expression of caspase-3 was increased in the primary rat chondrocytes treated with IL-1 β .

III-4. IL-1 β -induced chondrocyte death is involved with autophagy

Autophagy is a cellular process for protein degradation to remove a damaged organelles by lysosomes [27]. Therefore, an immunoblotting assay using autophagy-specific antibodies, such as beclin-1 and LC3, was performed to verify whether IL-1 β -induced chondrocyte death is related in autophagy. As shown in Fig. 5A, the expression of beclin-1 and LC3 was significantly increased in chondrocytes treated with IL-1 β . Furthermore, ICC and IHC results showed that the immunoreactivity of beclin-1 was increased by IL-1 β in primary rat chondrocytes and *ex vivo* organ-cultured articular cartilage (Fig. 5B). These results indicate that IL-1 β -induced cell death is accompanied by autophagy in chondrocytes.

A.



B.




Fig. 5. IL-1 β -induced chondrocytes death is involved with autophagy. Primary rat chondrocytes were treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, total proteins were extracted to perform the immunoblotting (A) using autophagy biomarkers such as beclin-1 and LC3. Primary rat chondrocytes cultured on 8-well chamber slides were treated with IL-1 β for 24 h. Thereafter, to verify the expression of beclin-1 in the primary rat chondrocytes treated with IL-1 β , ICC (B, upper panel) was performed. In addition, to verify the expression of beclin-1 in the articular cartilage treated with IL-1 β , explants of articular cartilage, dissected from rat knee joint, were treated with 10 and 50 ng/mL IL-1 β for 14 days. Then, IHC (B, lower panel) was performed. A, the expressions of autophagy biomarkers, such as beclin-1 and LC3, were increased by IL-1 β in primary rat chondrocytes. B, the expression of beclin-1 was upregulated by IL-1 β in both primary rat chondrocytes and articular cartilage.

III-5. IL-1 β induces the synthesis of 25-HC and its downstream oxysterol 7 α ,25-DHC in chondrocytes

To determine whether oxysterol is synthesized under inflammatory condition, primary rat chondrocytes were cultured with 10 and 50 ng/mL IL-1 β for 24 h. As shown in Fig. 6A and 6B, the qPCR and qRT-PCR results consistently showed that the level of *ch25h* mRNA, which encodes a CH25H enzyme that converts cholesterol to 25-HC, was significantly increased in the chondrocytes treated with IL-1 β . Sequentially, the level of *cyp7b1* mRNA, which encodes a CYP7B1 enzyme that converts 25-HC to 7 α ,25-DHC, was increased by IL-1 β in primary rat chondrocytes (Fig. 6A and 6B). Furthermore, immunoblotting assay showed that the expression of CH25H and CYP7B1 was upregulated in the chondrocytes treated with IL-1 β (Fig. 6C). As shown in Fig. 6D, the ICC results showed that immunoreactivities of CH25H and CYP7B1 were increased by IL-1 β in primary rat chondrocytes. Moreover, the relative production of 25-HC was increased by 1,084.50 \pm 120.21 pg/mL and 1,204.50 \pm 106.10 pg/mL in the chondrocytes treated with 10 and 50 ng/mL IL-1 β , respectively, compared with that of control cells (632.50 \pm 3.54 pg/mL) (Fig. 6E). These data indicate that IL-1 β induces the production of oxysterols such as 25-HC and 7 α ,25-DHC, through an increase in oxysterol synthases such as CH25H and CYP7B1, respectively, in primary rat chondrocytes.




Fig. 6. IL-1 β upregulates the production of 25-HC and its downstream oxysterol 7 α ,25-DHC through the expression of the CH25H-CYP7B1 axis in primary rat chondrocytes. Primary rat chondrocytes were treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, total RNA and total protein were isolated for qPCR (A), qRT-PCR (B), and immunoblotting (C) using specific antibodies oxysterol synthases, such as CH25H and CYP7B1. Primary rat chondrocytes cultured on the 8-well chamber slides were treated with 10 and 50 ng/mL IL-1 β for 24 h. Thereafter, ICC (D) was performed to verify the expression of CH25H and CYP7B1 in primary rat chondrocytes treated with IL-1 β . In addition, 25-HC ELISA (E) was performed to verify the production of 25-HC in primary rat chondrocytes treated with IL-1 β . A & B, mRNAs expression of *ch25h* and *cyp7b1* was induced by IL-1 β in primary rat chondrocytes. C & D, CH25H and CYP7b1 protein expression was upregulated in primary rat chondrocytes treated with IL-1 β . E, the production of 25-HC was increased by IL-1 β in primary rat chondrocytes.

III-6. 25-HC induces the progressive degeneration of articular cartilage via chondrocyte oxiaoptophagy

It has been reported that some oxysterols induce cell death via oxiaoptophagy [28]. Hence, to verify whether oxysterol 25-HC-induced chondrocyte death is involved in oxiaoptophagy, primary rat chondrocytes were treated with 10 and 20 $\mu\text{g/mL}$ 25-HC for 24 h. As shown in Fig. 7A, the relative cell viability was measured to be $95.00 \pm 2.50\%$ and $81.78 \pm 2.42\%$ in chondrocytes treated with 10 and 20 $\mu\text{g/mL}$ 25-HC, compared with that of the untreated control ($100.04 \pm 3.08\%$). Moreover, the results of cell live/dead staining showed that the number of living chondrocytes was decreased by 25-HC in a dose-dependent manner (Fig. 7B). Sequentially, 25-HC not only upregulated the expression of cleaved caspase-3 and cleaved PARP (Fig. 7C) but also increased of caspase-3 activity in primary rat chondrocytes (Fig. 7D). In addition, ROS production was gradually upregulated by 25-HC in primary chondrocytes (Fig. 7E). The expression of autophagy biomarkers such as beclin-1 and LC3 increased in a dose-dependent manner by 25-HC in primary rat chondrocytes (Fig. 7F). Finally, the result of safranin-O & fast green staining showed that proteoglycan loss was significantly increased by 25-HC in the *ex vivo* organ-cultured explant of articular cartilage dissected from rat knee joints (Fig. 7G). These data suggest that chondrocyte death by IL-1 β -induced oxysterol 25-HC is involved in progressive articular degeneration through the acceleration of proteoglycan loss, which is mediated by oxiaoptophagy accompanied by oxidative stress, apoptosis and autophagy in primary rat chondrocytes.




Fig. 7. 25-HC induces the progressive degeneration of articular cartilage through chondrocyte death involving oxiaoptophagy, which is accompanied by apoptotic cell death, oxidative stress, and autophagy. Primary rat chondrocytes were treated with 10 and 20 $\mu\text{g/mL}$ 25-HC for 24 h. Thereafter, MTT assay (A), cell live/dead staining (B), immunoblotting (C), caspase-3/-7 activity staining (D) and H_2DCFDA staining (E) were performed to investigate cell viability, cell survival, activated caspase, and ROS production in primary chondrocytes treated with 25-HC. Total proteins were extracted from the primary chondrocytes treated with 25-HC to perform

immunoblotting (C & F). Explants of articular cartilage dissected from rat knee joints were cultured *ex vivo* in the presence of 10 and 20 $\mu\text{g/mL}$ 25-HC for 14 days. Thereafter, safranin-O & fast green staining (G) was performed to verify the 25-HC-induced proteoglycan loss in the explant of articular cartilage. A, 25-HC treatment decreased the viability of primary rat chondrocytes. B, cell survival was decreased in primary rat chondrocytes treated with 25-HC. C, 25-HC induced apoptosis in primary rat chondrocytes. D, the activity of caspases-3 was increased by 25-HC in primary rat chondrocytes. E, ROS production increased in primary rat chondrocytes treated with 25-HC. F, the expression of autophagy biomarkers was increased in primary rat chondrocytes treated with 25-HC. G, proteoglycan depletion was accelerated by 25-HC in the explants of articular cartilage dissected from rat knee joints.

III-7. $7\alpha,25$ -DHC accelerates the progressive degeneration of articular cartilage via chondrocyte oxiaapoptophagy

$7\alpha,25$ -DHC is a downstream oxysterol of 25-HC and is catalyzed by CYP7B1. To verify whether oxysterol $7\alpha,25$ -DHC-induced chondrocyte death is involved in oxiaapoptophagy, chondrocytes were treated with 25 and 50 $\mu\text{g/mL}$ $7\alpha,25$ -DHC for 48 h. As shown in Fig. 8A, relative cell viability was $79.00 \pm 1.96\%$ and $77.52 \pm 2.18\%$ in the chondrocytes treated with 25 and 50 $\mu\text{g/mL}$ $7\alpha,25$ -DHC, respectively, compared with that of the untreated control ($100.04 \pm 3.29\%$). Moreover, the result of cell live/dead staining showed that the number of living chondrocytes was decreased by $7\alpha,25$ -DHC in a dose-dependent manner (Fig. 8B). Sequentially, $7\alpha,25$ -DHC not only upregulated the expression of cleaved caspase-3 and cleaved PARP (Fig. 8C) but also increased of caspase-3 activity in primary rat chondrocytes (Fig. 8D). In addition, ROS production was gradually upregulated by $7\alpha,25$ -DHC in primary chondrocytes (Fig. 8E). Expressions of autophagy biomarkers were increased by $7\alpha,25$ -DHC in primary rat chondrocytes (Fig. 8F). Finally, the result of safranin-O & fast green staining showed that proteoglycan loss was significantly increased by $7\alpha,25$ -DHC in the *ex vivo* organ-cultured explant of articular cartilage dissected from rat knee joints (Fig. 8G). These results indicate that chondrocyte death by IL-1 β -induced oxysterol $7\alpha,25$ -DHC is similar to chondrocyte death induced by 25-HC.





Fig. 8. 7α,25-DHC induces the progressive degeneration of articular cartilage through chondrocyte oxiaoptophagy. Primary rat chondrocytes were treated with 10 and 20 μg/mL 7α,25-DHC for 48 h. Thereafter, MTT assay (A), cell live/dead staining (B), immunoblotting (C), caspase-3/-7 activity staining (D), and H₂DCFDA staining (E) were performed to investigate cell viability, cell survival, activated caspase, and ROS production in the primary chondrocytes treated with 7α,25-DHC. Total proteins were extracted from the primary chondrocytes treated with 7α,25-DHC to perform immunoblotting (C & F). Explants of articular cartilage dissected from rat knee joints were cultured *ex vivo* in the presence of 10 and 20 μg/mL 7α,25-DHC for 14 days.

Thereafter, safranin-O & fast green staining (G) was performed to verify the $7\alpha,25$ -DHC-induced proteoglycan loss in articular cartilage. A, $7\alpha,25$ -DHC treatment decreased the viability of primary rat chondrocytes. B, cell survival was decreased in primary rat chondrocytes treated with $7\alpha,25$ -DHC. C, $7\alpha,25$ -DHC induced apoptosis in primary rat chondrocytes. D, the activity of caspases-3 was increased by $7\alpha,25$ -DHC in primary rat chondrocytes. E, ROS production was increased in primary rat chondrocytes treated with $7\alpha,25$ -DHC. F, the expression of autophagy biomarkers was increased in primary rat chondrocytes treated with $7\alpha,25$ -DHC. G, proteoglycan depletion was accelerated by $7\alpha,25$ -DHC in the explants of articular cartilage dissected from rat knee joints.


III-8. NIBR189 counteracts $7\alpha,25$ -DHC-induced catabolic effects

To investigate whether the inhibition of EBI2, a receptor of $7\alpha,25$ -DHC, counteract the $7\alpha,25$ -DHC-induced oxiaoptophagy, primary rat chondrocytes were treated with $7\alpha,25$ -DHC in the presence or absence of EBI2 antagonist NIBR189. As shown in Fig. 9A, results of MTT assay showed that relative viability of primary rat chondrocytes was measured by $100.00 \pm 2.64\%$ and $91.16 \pm 3.21\%$ in the absence or presence of NIBR189, respectively. The relative viability was decreased by $71.30 \pm 1.47\%$ in primary chondrocytes treated with $7\alpha,25$ -DHC (Fig. 9A). However, relative viability was measured by $75.28 \pm 1.67\%$ in the chondrocytes co-treated with $7\alpha,25$ -DHC and NIBR189 (Fig. 9A). Hence, these data demonstrate that NIBR189 counteracts $7\alpha,25$ -DHC-induced cytotoxicity in primary chondrocytes. Moreover, cell live/dead staining showed that $7\alpha,25$ -DHC decreased the number of live cells stained with green fluorescence, but it was counteracted by NIBR189 in primary rat chondrocytes. Sequentially, the expression of pro-apoptotic factors such as cleaved caspase-3 and cleaved PARP was upregulated in the primary rat chondrocytes treated with $7\alpha,25$ -DHC, but it was counteracted by NIBR189 (Fig. 9C). In addition, the upregulation of caspase-3/-7 activity by $7\alpha,25$ -DHC was also reduced by NIBR189 in primary rat chondrocytes (Fig 9D). NIBR189 not only suppress $7\alpha,25$ -DHC-induced ROS production (Fig. 9E) but also counteracted the expression of $7\alpha,25$ -DHC-induced autophagy biomarkers in primary rat chondrocytes (Fig. 9F). Finally, the result of safranin-O & fast green staining showed that NIBR189 suppressed proteoglycan loss by $7\alpha,25$ -DHC in *ex vivo* organ-cultured articular cartilage (Fig. 9G).


A.




B.




D.




C.



E.



F.



G.




Fig. 9. NIBR189 counteracts 7 α ,25-DHC-induced catabolic effects. Primary rat chondrocytes were treated with 50 μ g/mL 7 α ,25-DHC in the presence or absence of NIBR189 for 48 h. Thereafter, MTT assay (A) and cell live/dead staining were performed to investigate the viability and survival of chondrocytes, respectively. Total protein was collected to perform the immunoblot (C & F), caspase-3/-7 activity staining (D) and H₂DCFDA staining (E) were performed to investigate the activated caspase and ROS production in the primary chondrocytes treated with 50 μ g/mL 7 α ,25-DHC in the presence or absence of NIBR189. Explants of articular cartilage dissected from rat knee joint were incubated with 50 μ g/mL 7 α ,25-DHC in presence or absence of NIBR189, a receptor antagonist of 7 α ,25-DHC, for 14 days. Thereafter, safranin-O & fast green staining (G) was performed to verify the proteoglycan loss in articular cartilage. A, NIBR189 rescued the viability of primary rat chondrocytes in the presence of 7 α ,25-DHC. B & C, the expressions of apoptosis biomarkers, such as cleaved caspase-3 and PARP, were decreased by NIBR189 in the rat primary chondrocytes treated with 7 α ,25-DHC. D, NIBR189 suppressed the activation and expression of caspase-3 in the primary rat chondrocytes treated with 7 α ,25-DHC. E, the increase of ROS associated with oxidative stress was rescued by NIBR189 in the rat primary chondrocytes treated with 7 α ,25-DHC. F, NIBR189 significantly suppressed the expression of autophagy biomarkers such as LC3 and beclin-1 in the primary rat chondrocytes treated with 7 α ,25-DHC. G, 7 α ,25-DHC-induced proteoglycan depletion was significantly suppressed by NIBR189 in the *ex vivo* organ-cultured articular cartilage.

III-9. NIBR189 counteracts IL-1 β -induced arthritis through the inhibition of chondrocyte oxiapoptophagy

In accordance with previous results of this study, IL-1 β -induced oxysterols such as 25-HC and 7 α ,25-DHC were involved in the progressive degeneration of articular cartilage through the induction of chondrocyte oxiapoptophagy. Hence, to verify whether the inhibition of EBI2 might attenuate IL-1 β -induced arthritis, explants of articular cartilage dissected from rat knee joints were *ex vivo* cultured with 50 ng/mL IL-1 β in the presence or absence of 10 μ M NIBR189 for 14 days. Thereafter, safranin-O & fast green staining was performed to verify the alteration of proteoglycans in articular cartilage. As shown in Fig. 10A, proteoglycan loss was significantly increased by IL-1 β , but counteracted by NIBR189. Furthermore, mRNAs associated with ECM components, such as aggrecan and col II, decreased by 50 ng/mL IL-1 β , compared with the untreated control (Fig. 10B). However, it was significantly counteracted by 10 μ M NIBR189 in primary rat chondrocytes (Fig. 10B). Therefore, these data demonstrate that the inhibition of EBI2 attenuates the progressive degeneration of articular cartilage through the inhibition of IL-1 β -induced proteoglycan loss in articular cartilage and the loss of ECM components by IL-1 β in primary rat chondrocytes.

To verify whether NIBR189 suppresses IL-1 β -induced catabolic effects owing to the progressive degeneration of articular cartilage mediated by the expression and activation of cartilage-degrading enzymes, primary rat chondrocytes were treated with IL-1 β in the presence or absence of NIBR189. Thereafter, qPCR, qRT-PCR, immunoblotting, and gelatin zymography were performed to assess alterations in cartilage-degrading enzymes. As shown in Fig. 11A - 11C, the expression of MMP-1, -3, and -13 significantly increased in the chondrocytes treated with IL-1 β , compared with that in the untreated control, whereas it was significantly counteracted by NIBR189. As shown in Fig. 11D, the upregulated activity of cartilage-degrading enzymes in the primary rat chondrocytes treated with IL-1 β was also decreased by NIBR189. These data indicate that the inhibition of EBI2 has an anti-catabolic effect

through the suppression of cartilage-degrading enzymes in primary rat chondrocytes treated with IL-1 β .

Next, to determine whether NIBR189 suppresses the IL-1 β -induced inflammatory mediators, an arthritis risk factor, primary rat chondrocytes were cultured with 50 ng/mL of IL-1 β in the presence or absence of 10 μ M NIBR189 for 24 h. Thereafter, mRNA and protein level of inflammatory mediators, such as iNOS and COX-2, were assessed by qPCR, immunoblotting, NO measurements, and PGE₂ measurements. As shown in Fig. 12A - 12C, mRNA and protein level of iNOS and COX-2 were significantly increased by 50 ng/mL IL-1 β , but were counteracted by NIBR189 in chondrocytes. Sequentially, the increase of NO and PGE₂ production by IL-1 β was also counteracted by NIBR189 in primary rat chondrocytes (Fig. 12D and 12E). Hence, these data suggest that the inhibition of EB12 has anti-catabolic effects mediated by the suppression of inflammatory mediators in the chondrocytes treated with IL-1 β .


To verify whether NIBR189 suppresses IL-1 β -induced chondrocyte apoptosis, primary rat chondrocytes were treated with IL-1 β and NIBR189. As shown in Fig. 13A, the MTT assay showed that the relative viabilities of primary rat chondrocytes were measured to be 100.00 \pm 0.37% or 94.82 \pm 1.42% in the absence or presence of NIBR189, respectively. The relative viability decreased by 84.90 \pm 0.40% in primary chondrocytes treated with IL-1 β (Fig. 13A). However, relative viability was measured to be 87.72 \pm 1.25% in chondrocytes co-treated with IL-1 β and NIBR189 (Fig. 13A). Hence, these data demonstrate that NIBR189 counteracts IL-1 β -induced cytotoxicity in primary chondrocytes. Cell live/dead staining showed that IL-1 β decreased the number of live cells that presented green fluorescence, but it was counteracted by NIBR189 in primary rat chondrocytes (Fig. 13B). Sequentially, the expression of pro-apoptotic factors such as cleaved caspase-8, -9, and -3, and cleaved PARP were upregulated in primary rat chondrocytes treated with IL-1 β (Fig. 13C). In contrast, the expression of pro-apoptotic factors was significantly downregulated in the primary rat chondrocytes co-treated with IL-1 β and NIBR189 (Fig. 13C). In addition, the upregulation of caspase-3/-7 activity by IL-1 β was also decreased by NIBR189 in primary rat chondrocytes (Fig. 13D upper panel). Furthermore, ICC and

IHC results showed that the immunoreactivity of caspase-3 was increased by IL-1 β , but it was counteracted by NIBR189 in chondrocytes and *ex vivo* organ-cultured articular cartilage, as shown in Fig. 13D (middle and lower panel). Therefore, these data indicate that the inhibition of EBI2 has an anti-catabolic effect against IL-1 β -induced chondrocyte apoptosis.

To determine whether NIBR189 suppresses IL-1 β -induced chondrocyte autophagy, primary rat chondrocytes were treated with IL-1 β in the presence or absence of NIBR189. NIBR189 counteracted the expression of IL-1 β -induced autophagy biomarkers such as beclin-1 and LC3 in the primary rat chondrocytes with IL-1 β (Fig. 14A). Finally, the results of ICC and IHC showed that the upregulation of beclin-1 by IL-1 β was reduced by NIBR189 in *ex vivo* organ-cultured articular cartilage in the presence of IL-1 β (Fig. 14B). Therefore, these data indicate that the inhibition of EBI2 suppresses IL-1 β -induced autophagy in primary rat chondrocytes.

Overall, these results consistently suggest that the inhibition of EBI2 may attenuate IL-1 β -induced arthritis through the suppression of autophagy in primary rat chondrocytes.

A.



B.






Fig. 10. NIBR189 counteracts IL-1 β -induced catabolic effects. Explants of articular cartilage dissected from rat knee joint were incubated with 50 ng/mL IL-1 β in presence or absence of NIBR189, a receptor antagonist of 7 α ,25-DHC, for 14 days. Thereafter, safranin-O & fast green staining (A) was performed to verify the proteoglycan loss in articular cartilage. In addition, to verify the alteration of mRNAs associated with the ECM components, rat primary chondrocytes were treated with 50 ng/mL IL-1 β in presence or absence of NIBR189 for 24 h. Thereafter, mRNAs were isolated to perform the qPCR (B). A, IL-1 β -induced proteoglycan depletion was significantly suppressed by NIBR189 in *ex vivo* organ-cultured articular cartilage. B, the reduction of mRNAs associated with ECM components was rescued by NIBR189 in the rat primary chondrocytes treated with IL-1 β .


A.



B.



C.



D.






Fig. 11. NIBR189 suppresses the expression and activation of cartilage degrading enzymes in the primary rat chondrocytes treated with IL-1 β . Primary rat chondrocytes were treated with 50 ng/mL IL-1 β in the presence or absence of NIBR189 for 24 h. Thereafter, total RNA, total protein, and conditioned media were collected to perform the qPCR (A), qRT-PCR (B), immunoblotting (C) using specific antibodies associated with cartilage degrading enzymes, such as MMP-1, -3, and -13, and gelatin zymography (D). A & B, the mRNAs encoded the *mmp-1*, -3, and -13 were significantly rescued by NIBR189 in primary rat chondrocytes treated with IL-1 β . C, the expressions of MMP-1, -3, and -13 proteins were significantly decreased by NIBR189 in primary rat chondrocytes treated with IL-1 β . D, the activation of MMPs were decreased by NIBR189 in the conditioned media collected from primary rat chondrocytes treated with IL-1 β .


A.




B.



C.



D.



E.






Fig. 12. NIBR189 suppresses the expression and production of inflammatory mediators in the primary rat chondrocytes treated with IL-1 β . Primary rat chondrocytes were treated with 50 ng/mL IL-1 β in the presence or absence of NIBR189 for 24 h. Thereafter, total RNA and total protein were collected to perform the qPCR (A), qRT-PCR (B), immunoblotting (C) using specific antibodies associated with inflammatory mediators, NO assay (D), and PGE₂ ELISA (E). A & B, the mRNAs encoded the *inos* and *cox-2* were significantly decreased by NIBR189 in the primary rat chondrocytes treated with IL-1 β . C, the expression of iNOS and COX-2 was significantly downregulated by NIBR189 in primary rat chondrocytes treated with IL-1 β . D, the production of NO was significantly decreased by NIBR189 in primary rat chondrocytes treated with IL-1 β . E, the production of PGE₂ was significantly decreased by NIBR189 in the primary rat chondrocytes treated with IL-1 β .


A.



B.



C.



D.




Fig. 13. NIBR189 suppresses IL-1 β -induced chondrocytes apoptosis. Primary rat chondrocytes were treated with 50 ng/mL IL-1 β in the presence or absence of NIBR189 for 24 h. Thereafter, MTT assay (A) and cell live/dead staining (B) were performed to investigate viability and survival of chondrocytes, respectively. Total proteins were extracted to perform the immunoblotting (C) using apoptotic specific biomarkers such as caspase-8, -9, -3, and PARP. In addition, caspase-3/-7 activity (D, upper panel) and ICC (D, middle panel) were performed to investigate activation and expression of caspase-3 in the primary rat chondrocytes treated with IL-1 β and NIBR189. The explants of articular cartilage dissected from rat knee joint were treated with IL-1 β in the presence or absence of NIBR189 for 14 days. Thereafter, IHC (D, lower panel) was performed to investigate the expression of caspase-3. A & B, NIBR189 rescued the viability of primary rat chondrocyte in the presence of IL-1 β . C, expression of apoptosis biomarkers was decreased by NIBR189 in rat primary chondrocytes treated with IL-1 β . D, NIBR189 suppressed the activation and expression of caspase-3 in both primary rat chondrocytes and *ex vivo* organ-cultured articular cartilage treated with IL-1 β .




Fig. 14. NIBR189 suppresses IL-1 β -induced autophagy in primary rat chondrocytes. Primary rat chondrocytes were treated with 50 ng/mL IL-1 β in the presence or absence of NIBR189 for 24 h. Thereafter, total proteins were collected to perform immunoblotting (A) using specific autophagy biomarkers. To verify the NIBR189-mediated autophagy suppression in both primary rat chondrocytes and articular cartilage, ICC (B, upper panel) and IHC (B, lower panel) were performed using autophagy specific biomarker beclin-1. A, NIBR189 significantly suppressed the IL-1 β -induced LC3 and beclin-1 expressions in primary rat chondrocytes. B, NIBR189 suppressed the expression of beclin-1 in both primary rat chondrocytes and *ex vivo* organ-cultured explants of articular cartilage dissected from rat knee joint.

IV. DISCUSSION

Recent studies have reported several representative catabolic risk factors of arthritis, including ROS (such as NO and superoxide anions), pro-inflammatory cytokines (such as IL-1 β , Interleukin-6, Interleukin-8 and tumor necrosis factor α), and pain-associated molecules (such as substance-P and PGE₂) [18, 29]. These catabolic risk factors can initiate the progressive degeneration of articular cartilage through the accelerating breakdown of the ECM by either the upregulation of cartilage-degrading enzymes and the suppression of tissue inhibitor of metalloproteinases and ECM, components such as Col II and aggrecan, which are regulated by chondrocytes [30].

The pathophysiological etiology of arthritis has been reported to be closely related to aging, traumatic joint injury, severe mechanical joint movement, obesity, individual genetic characteristics, and sex [31]. However, the pathophysiological etiology of arthritis remains largely unknown because it is caused by multiple factors such as one or a combination of more pathophysiological etiologies [32].

Aging, a representative pathophysiological etiology of arthritis, induces chronic low-grade inflammation, referred to as inflammaging [11]. Furthermore, traumatic joint injury and severe mechanical joint movement are the pathophysiological etiology of arthritis as they increase the inflammatory conditions due to chronic overload on the articular cartilage of synovial joints [6]. In addition, genetic disorders associated with the immune system also act as a pathophysiological etiology of arthritis through the upregulation of inflammation at the synovial joint [33]. The menopause also acts as a risk factor for arthritis as it increases inflammation due to hormonal change-mediated stress in elderly women [34]. Hence, inflammation caused by these pathophysiological factors at the synovial joint is a crucial risk factor for arthritis.

In the present study, the representative pro-inflammatory cytokine IL-1 β induced arthritis, mediated by the progressive degeneration of articular cartilage via the acceleration of proteoglycan loss was studied in an *ex vivo* organ-cultured explant of articular cartilage dissected from a rat knee joint (Fig. 1A). Sequentially, IL-1 β -induced arthritis was mediated by the suppression of ECM components, such as

aggrecan and Col II (Fig. 1B), the expression and activation of cartilage-degrading enzymes such as MMP-1, -3, and -13 (Fig. 2), and an increase of inflammatory mediators, including iNOS, COX-2, NO, and PGE₂ (Fig. 3) in primary rat chondrocytes.

Apoptosis is a precisely regulated process associated with cell death during development, homeostasis, and aging [8]. Furthermore, dysregulation of apoptosis is closely related to the pathogenesis of degenerative diseases [8]. In particular, the apoptosis of chondrocytes, which are specialized cells for the maintenance of the ECM, leads to the progressive degeneration of articular cartilage and is observed in the articular cartilage during the late-stage of arthritis [8, 35]. Del Carlo et al. reported that inflammatory mediators, such as NO and superoxide anions, are the key factors that induce the apoptosis of chondrocytes [36]. In addition, the IL-1 family, including Interleukin-1 α and IL-1 β , the representative pro-inflammatory cytokine mediating the progressive degeneration of articular cartilage, is reported to decrease the viability of chondrocytes [37]. Hence, these results suggest that the apoptosis of chondrocytes is related to persistently high levels of inflammation, which could augment the progressive degeneration of articular cartilage [8]. As shown in Fig. 4, present study demonstrated that IL-1 β decreased the viability of chondrocytes through apoptosis mediated by the cascade activation of pro-apoptotic caspases, such as caspase-8, -9, and -3. Furthermore, the expression of both cleaved caspase-8 and -9 was gradually increased by IL-1 β in primary rat chondrocytes. These results indicate that IL-1 β -induced chondrocyte apoptosis is mediated by the mitochondrial-dependent intrinsic apoptosis pathway.

In addition, present study demonstrated that the expression of autophagy-related biomarkers, such as beclin-1 and LC3, was significantly increased in both chondrocytes and articular cartilage under IL-1 β -induced inflammatory conditions (Fig. 5). Autophagy, a cellular homeostatic mechanism, regulates cell death and inflammation through interaction with various types of stimuli, including metabolic stress and oxygen depletion [37-39]. Furthermore, autophagy has been associated with a complex cross-talk with apoptosis through the sharing with beclin-1, which is identified as a Bcl-2 interacting protein possessing a Bcl-2 homology 3 domain to bind Bcl-2 and

B-cell lymphoma-extra large (Bcl-xL) [40, 41]. Hence, the upregulation of the anti-apoptotic factor Bcl-2 can suppress the autophagic function of beclin-1 [42]. Moreover, the inhibition of death receptor-mediated extrinsic apoptosis, mediated by the caspase-8 and -3 axis, suppresses autophagy through a direct interaction with autophagy-relevant factors, such as LC3 [43]. Therefore, many studies have shown that autophagy accompanied by apoptosis is closely associated with the pathogenesis of arthritis [35, 44]. Taken together, these data suggest that IL-1 β -induced arthritis is involved in apoptosis and autophagy in chondrocytes.

Recent studies have shown that metabolic syndromes, including obesity, hyperlipidemia, hypercholesterolemia, and hypertension, act as the pathophysiological risk etiologies of arthritis, including OA [45], RA [46-48], psoriatic arthritis [49], gout [50], and juvenile idiopathic arthritis [51]. Metabolic syndromes are closely associated with systemic inflammation [52]. Hence, recent studies associated with the pathophysiological etiology of arthritis have been conducted to investigate the aspects of metabolic diseases [53, 54]. In accordance with this attempt, cholesterol metabolism associated with metabolic syndrome, is attracting attention as a crucial risk factor for arthritis [55]. Aksu et al. reported that the levels of oxysterols, the metabolites of cholesterol, are significantly increased in patients with silicosis-related complications, including RA, systemic sclerosis, and vasculitis, which indicates a correlation between cholesterol oxidation, lipid peroxidation, and silicosis [56]. More recently, Choi et al. reported that cholesterol metabolism, mediated by the CH25H-CYP7B1-ROR α axis, is closely associated with the pathogenesis of OA [24]. These reports consistently indicate that the pathogenesis of arthritis is involved in the biological linkage between inflammation and cholesterol metabolism [24, 56]. Hence, in this study, the expression and synthesis of oxysterols were investigated in both articular cartilage and chondrocytes under representative pro-inflammatory cytokine IL-1 β -induced arthritic conditions.

As shown in Fig. 6, IL-1 β not only increased the expression of oxysterol synthases, such as CH25H and CYP7B1, but also upregulated the synthesis of 25-HC in chondrocytes. Hence, these data indicate that IL-1 β -induced arthritis is accompanied by the synthesis of oxysterols such as 25-HC and 7 α ,25-DHC. Furthermore, these results

indicate that IL-1 β -induced chondrocyte death involves oxiaoptophagy, which is a cell death accompanied by oxidative stress, apoptosis, and autophagy.

Previous studies have reported that oxysterol induces apoptosis in various types of cells, such as human monocytic cell lines (e.g., U-937 and HL-60) [57], human lymphoblastic leukemia CEM cells [58], human vascular smooth muscle cells [59], and presumptive endothelial cell line ECV-304 cells [60]. Additionally, it has been reported that some oxysterols induce oxiaoptophagy, a type of cell death involved in oxidative stress, apoptosis, and autophagy [61]. In particular, Kostopoulou et al. reported that sterol regulatory element binding transcription factor 2 (SREBP-2), a transcription factor associated with the pathogenesis of OA, was upregulated in OA chondrocytes treated with 25-HC [16]. Furthermore, Seo et al. reported that 25-HC is a metabolic pathophysiological factor of OA through an increase in chondrocyte apoptosis [62]. Taken together, the previous studies and the results of this study suggest that IL-1 β -induced arthritis could be involved in oxysterol-induced chondrocyte oxiaoptophagy during the progressive degeneration of articular cartilage.

Oxysterols, cholesterol derivatives with 27 carbon atoms, are natural materials that are regulated by cholesterol metabolism in the human body and are involved in many physiological functions, such as several signaling pathways, membrane fluidity, and activity for some membrane proteins at very low concentrations [63-65]. However, some oxysterols are associated with the pathogenesis of several human diseases, such as atherosclerosis, Alzheimer's disease, Parkinson's disease, and even cancer [66]. Generally, oxysterols are synthesized from cholesterol via enzymatic and non-enzymatic pathways [67]. The enzymatic pathways are mainly mediated by the synthesis of side-chain oxysterols by the cytochrome P450 (CYP) family and CH25H [65]. In contrast, non-enzymatic pathways associated with the generation of ring-oxysterols are mediated by ROS [67]. Hence, various types of oxysterols are synthesized from cholesterol via enzymatic and non-enzymatic pathways [67].

The oxysterol 25-HC is generated from cholesterol by CH25H and ROS under inflammatory conditions [65]. Recent studies have reported that 25-HC not only amplifies the production of IL-1 β in microglial cells [68] but also contributes to cerebral inflammation of X-linked adrenoleukodystrophy via the activation of the

NLRP3 inflammasome [69]. In addition, previous studies have reported that 25-HC induces apoptosis in various types of cells such as human aortic smooth muscle cells [70], human leukemic cell line CEM [71], oligodendrocytes [72], rat Leydig cells [73], and rat pheochromocytoma cell line PC12 [74]. Furthermore, Olivier et al. reported that 25-HC induces both P2X7-dependent pyroptosis, a type of cell death mediated by inflammation, and caspase-dependent apoptosis in human keratinocytes [21]. In particular, Kostopoulou et al. reported that SREBP-2, a transcription factor associated with the pathogenesis of OA, is upregulated in OA chondrocytes treated with 25-HC [16]. Seo et al. reported that 25-HC acts as a metabolic pathophysiological factor of OA by increasing chondrocyte apoptosis [62]. Therefore, previous studies have indicated that 25-HC induces chondrocyte death mediated by inflammation-mediated oxidative stress, apoptosis, and autophagy in chondrocytes.

The present study demonstrated that 25-HC induced caspase-dependent apoptosis (Fig. 7A-7D), upregulation of ROS production (Fig. 7E), and expression of autophagy biomarkers (Fig. 7F). Finally, 25-HC induced progressive degeneration of articular cartilage via the acceleration of proteoglycan loss (Fig. 7G). Hence, these data suggest that 25-HC induces the degeneration of articular cartilage through oxiaoptophagy accompanied by oxidative stress, apoptosis, and autophagy in chondrocytes.

As shown in Fig. 6, the expression of CYP7B1 was significantly increased in primary rat chondrocytes treated with IL-1 β . CYP7B1, a member of the CYP family, synthesizes 7 α ,25-DHC from 25-HC [75]. Furthermore, 7 α ,25-DHC is known as the physiological ligand of EBI2 [25] and was recently discovered as immune regulator [76]. More recently, Choi et al. reported that the CH25H-CYP7B1 axis regulates the pathogenesis of OA [24]. Therefore, this study was undertaken to investigate whether 7 α ,25-DHC, a downstream oxysterol of 25-HC, could induce progressive degeneration of articular cartilage through chondrocyte oxiaoptophagy.

Similar to 25-HC, 7 α ,25-DHC not only decreased the viability of chondrocytes (Fig. 8A and 8B) but also induced the caspase-dependent apoptosis through the cascade activation of pro-apoptotic caspases in chondrocytes (Fig. 8C and 8D). Furthermore, the production of ROS (Fig. 8E) and the expression of autophagy

biomarkers (Fig. 8F) were significantly increased in chondrocytes treated with $7\alpha,25$ -DHC. Finally, $7\alpha,25$ -DHC induced progressive degeneration of articular cartilage via the acceleration of proteoglycan depletion. Furthermore, as shown in Fig. 9, NIBR189, an antagonist of EBI2, not only counteracted the $7\alpha,25$ -DHC-induced cytotoxicity and apoptosis but also suppressed both the production of ROS and the expression of autophagy biomarkers in chondrocytes. Moreover, NIBR189 ameliorated the $7\alpha,25$ -DHC-induced proteoglycan depletion in *ex vivo* organ-cultured explants of articular cartilage (Fig. 9). These data consistently demonstrate that the inhibition of EBI2 attenuates the progressive degeneration of articular cartilage through the suppression of $7\alpha,25$ -DHC-induced chondrocyte oxiaoptophagy, indicating that $7\alpha,25$ -DHC is a catabolic risk factor of arthritis through the oxiaoptophagy of chondrocytes. Moreover, these results suggest that the inhibition of EBI2 may have an anti-catabolic effect to prevent the progressive degeneration of articular cartilage by counteracting $7\alpha,25$ -DHC-induced chondrocyte oxiaoptophagy in the synovial joint under inflammatory conditions.

In addition, the inhibition of EBI2 counteracted significantly against IL-1 β -induced severe catabolic effects, such as proteoglycan depletion in *ex vivo* organ-cultured explants of articular cartilage (Fig. 10A), the suppression of ECM components (Fig. 10B), the expression and activation of cartilage-degrading enzymes (Fig. 11), and the upregulation of inflammatory mediators (Fig. 12). Furthermore, the inhibition of EBI2 not only ameliorated the IL-1 β -induced cytotoxicity and caspase-dependent apoptosis in chondrocytes (Fig. 13) but also counteracted IL-1 β -induced autophagy (Fig. 14). Furthermore, these data suggest that IL-1 β -induced arthritis may be involved in chondrocyte oxiaoptophagy by upregulating 25-HC and $7\alpha,25$ -DHC under inflammatory conditions. Therefore, these results consistently demonstrate that the inhibition of EBI2 has an anti-catabolic effect in preventing inflammation-induced arthritis.

In conclusion, the present study demonstrates that the pathogenesis of arthritis is associated with the oxiaoptophagy of chondrocytes, which is mediated by the catabolic oxysterols 25-HC and $7\alpha,25$ -DHC under inflammatory conditions.




Fig. 15. Schematic diagram of chondrocyte oxiaoptophagy regulated by 25-HC-7α,25-DHC-EB12 axis in arthritis.

VI. REFERENCE

- [1] P.A. Rockar, Jr., The subtalar joint: anatomy and joint motion, *J Orthop Sports Phys Ther* 21 (1995) 361-372. 10.2519/jospt.1995.21.6.361.
- [2] J.C. de Grauw, Molecular monitoring of equine joint homeostasis, *Vet Q* 31 (2011) 77-86. 10.1080/01652176.2011.565546.
- [3] F. Eckstein, M. Hudelmaier, R. Putz, The effects of exercise on human articular cartilage, *J Anat* 208 (2006) 491-512. 10.1111/j.1469-7580.2006.00546.x.
- [4] A.J. Sophia Fox, A. Bedi, S.A. Rodeo, The basic science of articular cartilage: structure, composition, and function, *Sports Health* 1 (2009) 461-468. 10.1177/1941738109350438.
- [5] M.B. Goldring, K.B. Marcu, Cartilage homeostasis in health and rheumatic diseases, *Arthritis Res Ther* 11 (2009) 224. 10.1186/ar2592.
- [6] Y. He, Z. Li, P.G. Alexander, B.D. Ocasio-Nieves, L. Yocum, H. Lin, R.S. Tuan, Pathogenesis of Osteoarthritis: Risk Factors, Regulatory Pathways in Chondrocytes, and Experimental Models, *Biology (Basel)* 9 (2020). 10.3390/biology9080194.
- [7] E. Charlier, B. Relic, C. Deroyer, O. Malaise, S. Neuville, J. Collee, M.G. Malaise, D. De Seny, Insights on Molecular Mechanisms of Chondrocytes Death in Osteoarthritis, *Int J Mol Sci* 17 (2016). 10.3390/ijms17122146.
- [8] H.S. Hwang, H.A. Kim, Chondrocyte Apoptosis in the Pathogenesis of Osteoarthritis, *Int J Mol Sci* 16 (2015) 26035-26054. 10.3390/ijms161125943.
- [9] D.J. Hunter, J.J. McDougall, F.J. Keefe, The symptoms of osteoarthritis and the genesis of pain, *Rheum Dis Clin North Am* 34 (2008) 623-643. 10.1016/j.rdc.2008.05.004.
- [10] R.F. Loeser, S.R. Goldring, C.R. Scanzello, M.B. Goldring, Osteoarthritis: a disease of the joint as an organ, *Arthritis Rheum* 64 (2012) 1697-1707. 10.1002/art.34453.
- [11] D. Furman, J. Campisi, E. Verdin, P. Carrera-Bastos, S. Targ, C. Franceschi, L. Ferrucci, D.W. Gilroy, A. Fasano, G.W. Miller, A.H. Miller, A. Mantovani, C.M. Weyand, N. Barzilai, J.J. Goronzy, T.A. Rando, R.B. Effros, A. Lucia, N. Kleinstreuer, G.M. Slavich, Chronic inflammation in the etiology of disease across the life span, *Nat Med* 25 (2019) 1822-1832. 10.1038/s41591-019-0675-0.
- [12] A. Valenzuela, J. Sanhueza, S. Nieto, Cholesterol oxidation: health hazard and the role of antioxidants in prevention, *Biol Res* 36 (2003) 291-302. 10.4067/s0716-97602003000300002.

- [13] W.J. Griffiths, Y. Wang, Oxysterol research: a brief review, *Biochem Soc Trans* 47 (2019) 517-526. 10.1042/BST20180135.
- [14] A.J. Brown, W. Jessup, Oxysterols and atherosclerosis, *Atherosclerosis* 142 (1999) 1-28. 10.1016/s0021-9150(98)00196-8.
- [15] A. Jusakul, P. Yongvanit, W. Loilome, N. Namwat, R. Kuver, Mechanisms of oxysterol-induced carcinogenesis, *Lipids Health Dis* 10 (2011) 44. 10.1186/1476-511X-10-44.
- [16] F. Kostopoulou, V. Gkretsi, K.N. Malizos, D. Iliopoulos, P. Oikonomou, L. Poultsides, A. Tsezou, Central role of SREBP-2 in the pathogenesis of osteoarthritis, *PLoS One* 7 (2012) e35753. 10.1371/journal.pone.0035753.
- [17] F.A. de Freitas, D. Levy, A. Zarrouk, G. Lizard, S.P. Bydlowski, Impact of Oxysterols on Cell Death, Proliferation, and Differentiation Induction: Current Status, *Cells* 10 (2021). 10.3390/cells10092301.
- [18] J. Dworzanski, M. Strycharz-Dudziak, E. Kliszczewska, M. Kielczykowska, A. Dworzanska, B. Drop, M. Polz-Dacewicz, Glutathione peroxidase (GPx) and superoxide dismutase (SOD) activity in patients with diabetes mellitus type 2 infected with Epstein-Barr virus, *PLoS One* 15 (2020) e0230374. 10.1371/journal.pone.0230374.
- [19] J.P. Kolb, Mechanisms involved in the pro- and anti-apoptotic role of NO in human leukemia, *Leukemia* 14 (2000) 1685-1694. 10.1038/sj.leu.2401896.
- [20] Y.K. Lee, J.A. Lee, Role of the mammalian ATG8/LC3 family in autophagy: differential and compensatory roles in the spatiotemporal regulation of autophagy, *BMB Rep* 49 (2016) 424-430. 10.5483/bmbrep.2016.49.8.081.
- [21] E. Olivier, M. Dutot, A. Regazzetti, O. Laprevote, P. Rat, 25-Hydroxycholesterol induces both P2X7-dependent pyroptosis and caspase-dependent apoptosis in human skin model: New insights into degenerative pathways, *Chem Phys Lipids* 207 (2017) 171-178. 10.1016/j.chemphyslip.2017.06.001.
- [22] J.S. You, H. Lim, T.H. Kim, J.S. Oh, G.J. Lee, Y.S. Seo, D.K. Kim, S.K. Yu, H.J. Kim, C.S. Kim, J.S. Kim, 25-Hydroxycholesterol Induces Death Receptor-mediated Extrinsic and Mitochondria-dependent Intrinsic Apoptosis in Head and Neck Squamous Cell Carcinoma Cells, *Anticancer Res* 40 (2020) 779-788. 10.21873/anticancer.14009.
- [23] S.M. Kim, M.Y. Noh, H. Kim, S.Y. Cheon, K.M. Lee, J. Lee, E. Cha, K.S. Park, K.W. Lee, J.J. Sung, S.H. Kim, 25-Hydroxycholesterol is involved in the pathogenesis of amyotrophic lateral sclerosis, *Oncotarget* 8 (2017) 11855-11867. 10.18632/oncotarget.14416.
- [24] W.S. Choi, G. Lee, W.H. Song, J.T. Koh, J. Yang, J.S. Kwak, H.E. Kim, S.K.

- Kim, Y.O. Son, H. Nam, I. Jin, Z.Y. Park, J. Kim, I.Y. Park, J.I. Hong, H.A. Kim, C.H. Chun, J.H. Ryu, J.S. Chun, The CH25H-CYP7B1-RORalpha axis of cholesterol metabolism regulates osteoarthritis, *Nature* 566 (2019) 254-258. 10.1038/s41586-019-0920-1.
- [25] S. Sun, C. Liu, 7alpha, 25-dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseases, *Front Pharmacol* 6 (2015) 60. 10.3389/fphar.2015.00060.
- [26] S. Hannedouche, J. Zhang, T. Yi, W. Shen, D. Nguyen, J.P. Pereira, D. Guerini, B.U. Baumgarten, S. Roggo, B. Wen, R. Knochenmuss, S. Noel, F. Gessier, L.M. Kelly, M. Vanek, S. Laurent, I. Preuss, C. Miault, I. Christen, R. Karuna, W. Li, D.I. Koo, T. Suply, C. Schmedt, E.C. Peters, R. Falchetto, A. Katopodis, C. Spanka, M.O. Roy, M. Detheux, Y.A. Chen, P.G. Schultz, C.Y. Cho, K. Seuwen, J.G. Cyster, A.W. Sailer, Oxysterols direct immune cell migration via EBI2, *Nature* 475 (2011) 524-527. 10.1038/nature10280.
- [27] N. Mizushima, Autophagy: process and function, *Genes Dev* 21 (2007) 2861-2873. 10.1101/gad.1599207.
- [28] T. Nury, A. Zarrouk, A. Yammine, J.J. Mackrill, A. Vejux, G. Lizard, Oxiaoptophagy: A type of cell death induced by some oxysterols, *Br J Pharmacol* 178 (2021) 3115-3123. 10.1111/bph.15173.
- [29] M.Y. Ansari, N. Ahmad, T.M. Haqqi, Oxidative stress and inflammation in osteoarthritis pathogenesis: Role of polyphenols, *Biomed Pharmacother* 129 (2020) 110452. 10.1016/j.biopha.2020.110452.
- [30] L. Troeberg, H. Nagase, Proteases involved in cartilage matrix degradation in osteoarthritis, *Biochim Biophys Acta* 1824 (2012) 133-145. 10.1016/j.bbapap.2011.06.020.
- [31] A. Shane Anderson, R.F. Loeser, Why is osteoarthritis an age-related disease?, *Best Pract Res Clin Rheumatol* 24 (2010) 15-26. 10.1016/j.berh.2009.08.006.
- [32] J.A. Stanich, J.D. Carter, J. Whittum-Hudson, A.P. Hudson, Rheumatoid arthritis: Disease or syndrome?, *Open Access Rheumatol* 1 (2009) 179-192. 10.2147/oarr.s7680.
- [33] J. Sokolove, C.M. Lepus, Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations, *Ther Adv Musculoskelet Dis* 5 (2013) 77-94. 10.1177/1759720X12467868.
- [34] F.R. Perez-Lopez, P. Chedraui, J.J. Gilbert, G. Perez-Roncero, Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era, *Fertil Steril* 92 (2009) 1171-1186. 10.1016/j.fertnstert.2009.06.032.

- [35] P. Castrogiovanni, S. Ravalli, G. Musumeci, Apoptosis and Autophagy in the Pathogenesis of Osteoarthritis, *J Invest Surg* 33 (2020) 874-875. 10.1080/08941939.2019.1576811.
- [36] M. Del Carlo, Jr., R.F. Loeser, Nitric oxide-mediated chondrocyte cell death requires the generation of additional reactive oxygen species, *Arthritis Rheum* 46 (2002) 394-403. 10.1002/art.10056.
- [37] A.J. Schuerwegh, E.J. Dombrecht, W.J. Stevens, J.F. Van Offel, C.H. Bridts, L.S. De Clerck, Influence of pro-inflammatory (IL-1 alpha, IL-6, TNF-alpha, IFN-gamma) and anti-inflammatory (IL-4) cytokines on chondrocyte function, *Osteoarthritis Cartilage* 11 (2003) 681-687. 10.1016/s1063-4584(03)00156-0.
- [38] B. Carames, N. Taniguchi, S. Otsuki, F.J. Blanco, M. Lotz, Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis, *Arthritis Rheum* 62 (2010) 791-801. 10.1002/art.27305.
- [39] J. Huang, G.Y. Lam, J.H. Brumell, Autophagy signaling through reactive oxygen species, *Antioxid Redox Signal* 14 (2011) 2215-2231. 10.1089/ars.2010.3554.
- [40] M.C. Maiuri, G. Le Toumelin, A. Criollo, J.C. Rain, F. Gautier, P. Juin, E. Tasdemir, G. Pierron, K. Troulinaki, N. Tavernarakis, J.A. Hickman, O. Geneste, G. Kroemer, Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1, *EMBO J* 26 (2007) 2527-2539. 10.1038/sj.emboj.7601689.
- [41] S. Sinha, B. Levine, The autophagy effector Beclin 1: a novel BH3-only protein, *Oncogene* 27 Suppl 1 (2008) S137-148. 10.1038/onc.2009.51.
- [42] J.P. Decuypere, J.B. Parys, G. Bultynck, Regulation of the autophagic bcl-2/beclin 1 interaction, *Cells* 1 (2012) 284-312. 10.3390/cells1030284.
- [43] M.M. Young, Y. Takahashi, O. Khan, S. Park, T. Hori, J. Yun, A.K. Sharma, S. Amin, C.D. Hu, J. Zhang, M. Kester, H.G. Wang, Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis, *J Biol Chem* 287 (2012) 12455-12468. 10.1074/jbc.M111.309104.
- [44] Y.S. Li, F.J. Zhang, C. Zeng, W. Luo, W.F. Xiao, S.G. Gao, G.H. Lei, Autophagy in osteoarthritis, *Joint Bone Spine* 83 (2016) 143-148. 10.1016/j.jbspin.2015.06.009.
- [45] A. Courties, J. Sellam, F. Berenbaum, Metabolic syndrome-associated osteoarthritis, *Curr Opin Rheumatol* 29 (2017) 214-222. 10.1097/BOR.0000000000000373.
- [46] S. Shaikh, A. Dahani, S.R. Arain, F. Khan, Metabolic Syndrome In Young Rheumatoid Arthritis Patients, *J Ayub Med Coll Abbottabad* 32 (2020) 318-322.

- [47] I. Ferraz-Amaro, C. Gonzalez-Juanatey, R. Lopez-Mejias, L. Riancho-Zarrabeitia, M.A. Gonzalez-Gay, Metabolic syndrome in rheumatoid arthritis, *Mediators Inflamm* 2013 (2013) 710928. 10.1155/2013/710928.
- [48] G. Kerekes, M.T. Nurmohamed, M.A. Gonzalez-Gay, I. Seres, G. Paragh, Z. Kardos, Z. Barath, L. Tamasi, P. Soltesz, Z. Szekanecz, Rheumatoid arthritis and metabolic syndrome, *Nat Rev Rheumatol* 10 (2014) 691-696. 10.1038/nrrheum.2014.121.
- [49] J.R. Tarn, D.W. Lendrem, J.D. Isaacs, In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis, *Expert Rev Clin Immunol* 16 (2020) 621-630. 10.1080/1744666X.2020.1771183.
- [50] G.E. Thottam, S. Krasnokutsky, M.H. Pillinger, Gout and Metabolic Syndrome: a Tangled Web, *Curr Rheumatol Rep* 19 (2017) 60. 10.1007/s11926-017-0688-y.
- [51] A. Zanette Cde, S.H. Machado, J.C. Brenol, R.M. Xavier, Metabolic syndrome and juvenile idiopathic arthritis, *Rev Bras Reumatol* 50 (2010) 190-204.
- [52] F. Bonomini, L.F. Rodella, R. Rezzani, Metabolic syndrome, aging and involvement of oxidative stress, *Aging Dis* 6 (2015) 109-120. 10.14336/AD.2014.0305.
- [53] R. Chadha, Revealed aspect of metabolic osteoarthritis, *J Orthop* 13 (2016) 347-351. 10.1016/j.jor.2016.06.029.
- [54] A. Mobasheri, M. Batt, An update on the pathophysiology of osteoarthritis, *Ann Phys Rehabil Med* 59 (2016) 333-339. 10.1016/j.rehab.2016.07.004.
- [55] J. Xiong, J. Long, X. Chen, Y. Li, H. Song, Dyslipidemia Might Be Associated with an Increased Risk of Osteoarthritis, *Biomed Res Int* 2020 (2020) 3105248. 10.1155/2020/3105248.
- [56] N. Aksu, A. Samadi, A. Yalcinkaya, T. Cetin, B. Eser, I. Lay, T.N. Ozis, Y. Oztas, S. Sabuncuoglu, Evaluation of oxysterol levels of patients with silicosis by LC-MS/MS method, *Mol Cell Biochem* 467 (2020) 117-125. 10.1007/s11010-020-03706-w.
- [57] K. Aupeix, D. Weltin, J.E. Mejia, M. Christ, J. Marchal, J.M. Freyssinet, P. Bischoff, Oxysterol-induced apoptosis in human monocytic cell lines, *Immunobiology* 194 (1995) 415-428. 10.1016/S0171-2985(11)80108-7.
- [58] S. Ayala-Torres, F. Zhou, E.B. Thompson, Apoptosis induced by oxysterol in CEM cells is associated with negative regulation of c-myc, *Exp Cell Res* 246 (1999) 193-202. 10.1006/excr.1998.4308.
- [59] Y. Miyashita, H. Ozaki, N. Koide, M. Otsuka, T. Oyama, Y. Itoh, T. Mastuzaka, K. Shirai, Oxysterol-induced apoptosis of vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitor, pravastatin, *J Atheroscler*

- Thromb 9 (2002) 65-71. 10.5551/jat.9.65.
- [60] H. Liu, C. Zhang, K. Huang, Lanthanum chloride suppresses oxysterol-induced ECV-304 cell apoptosis via inhibition of intracellular Ca(2+) concentration elevation, oxidative stress, and activation of ERK and NF-kappaB signaling pathways, *J Biol Inorg Chem* 16 (2011) 671-681. 10.1007/s00775-011-0766-y.
- [61] M.E. Fisfalen, L.J. DeGroot, J. Quintans, W.A. Franklin, K. Soltani, Microsomal antigen-reactive lymphocyte lines and clones derived from thyroid tissue of patients with Graves' disease, *J Clin Endocrinol Metab* 66 (1988) 776-784. 10.1210/jcem-66-4-776.
- [62] Y.S. Seo, I.A. Cho, T.H. Kim, J.S. You, J.S. Oh, G.J. Lee, D.K. Kim, J.S. Kim, Oxysterol 25-hydroxycholesterol as a metabolic pathophysiological factors of osteoarthritis induces apoptosis in primary rat chondrocytes, *Korean J Physiol Pharmacol* 24 (2020) 249-257. 10.4196/kjpp.2020.24.3.249.
- [63] W.J. Griffiths, P.J. Crick, Y. Wang, Methods for oxysterol analysis: past, present and future, *Biochem Pharmacol* 86 (2013) 3-14. 10.1016/j.bcp.2013.01.027.
- [64] V. Mutemberezi, O. Guillemot-Legris, G.G. Muccioli, Oxysterols: From cholesterol metabolites to key mediators, *Prog Lipid Res* 64 (2016) 152-169. 10.1016/j.plipres.2016.09.002.
- [65] A. Kloudova, F.P. Guengerich, P. Soucek, The Role of Oxysterols in Human Cancer, *Trends Endocrinol Metab* 28 (2017) 485-496. 10.1016/j.tem.2017.03.002.
- [66] W. Kulig, L. Cwiklik, P. Jurkiewicz, T. Rog, I. Vattulainen, Cholesterol oxidation products and their biological importance, *Chem Phys Lipids* 199 (2016) 144-160. 10.1016/j.chemphyslip.2016.03.001.
- [67] W.J. Griffiths, Y. Wang, Oxysterols as lipid mediators: Their biosynthetic genes, enzymes and metabolites, *Prostaglandins Other Lipid Mediat* 147 (2020) 106381. 10.1016/j.prostaglandins.2019.106381.
- [68] M.Y. Wong, M. Lewis, J.J. Doherty, Y. Shi, A.G. Cashikar, A. Amelianchik, S. Tymchuk, P.M. Sullivan, M. Qian, D.F. Covey, G.A. Petsko, D.M. Holtzman, S.M. Paul, W. Luo, 25-Hydroxycholesterol amplifies microglial IL-1beta production in an apoE isoform-dependent manner, *J Neuroinflammation* 17 (2020) 192. 10.1186/s12974-020-01869-3.
- [69] J. Jang, S. Park, H. Jin Hur, H.J. Cho, I. Hwang, Y. Pyo Kang, I. Im, H. Lee, E. Lee, W. Yang, H.C. Kang, S. Won Kwon, J.W. Yu, D.W. Kim, 25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome, *Nat Commun* 7 (2016) 13129. 10.1038/ncomms13129.
- [70] M.P. Ares, M.I. Porn-Ares, J. Thyberg, L. Juntti-Berggren, P.O. Berggren, U.

- Diczfalusy, B. Kallin, I. Bjorkhem, S. Orrenius, J. Nilsson, Ca²⁺ channel blockers verapamil and nifedipine inhibit apoptosis induced by 25-hydroxycholesterol in human aortic smooth muscle cells, *J Lipid Res* 38 (1997) 2049-2061.
- [71] S. Ayala-Torres, P.C. Moller, B.H. Johnson, E.B. Thompson, Characteristics of 25-hydroxycholesterol-induced apoptosis in the human leukemic cell line CEM, *Exp Cell Res* 235 (1997) 35-47. 10.1006/excr.1997.3630.
- [72] A. Trousson, S. Bernard, P.X. Petit, P. Liere, A. Pianos, K. El Hadri, J.M. Lobaccaro, M.S. Ghandour, M. Raymondjean, M. Schumacher, C. Massaad, 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR, *J Neurochem* 109 (2009) 945-958. 10.1111/j.1471-4159.2009.06009.x.
- [73] C. Travert, S. Carreau, D. Le Goff, Induction of apoptosis by 25-hydroxycholesterol in adult rat Leydig cells: protective effect of 17beta-estradiol, *Reprod Toxicol* 22 (2006) 564-570. 10.1016/j.reprotox.2006.05.006.
- [74] Y.K. Choi, Y.S. Kim, I.Y. Choi, S.W. Kim, W.K. Kim, 25-hydroxycholesterol induces mitochondria-dependent apoptosis via activation of glycogen synthase kinase-3beta in PC12 cells, *Free Radic Res* 42 (2008) 544-553. 10.1080/10715760802146062.
- [75] J. Jia, T.M. Conlon, R.S. Sarker, D. Tasdemir, N.F. Smirnova, B. Srivastava, S.E. Verleden, G. Gunes, X. Wu, C. Prehn, J. Gao, K. Heinzlmann, J. Lintelmann, M. Irmler, S. Pfeiffer, M. Schloter, R. Zimmermann, M. Hrabe de Angelis, J. Beckers, J. Adamski, H. Bayram, O. Eickelberg, A.O. Yildirim, Cholesterol metabolism promotes B-cell positioning during immune pathogenesis of chronic obstructive pulmonary disease, *EMBO Mol Med* 10 (2018). 10.15252/emmm.201708349.
- [76] T. Raselli, T. Hearn, A. Wyss, K. Atrott, A. Peter, I. Frey-Wagner, M.R. Spalinger, E.M. Maggio, A.W. Sailer, J. Schmitt, P. Schreiner, A. Moncsek, J. Mertens, M. Scharl, W.J. Griffiths, M. Bueter, A. Geier, G. Rogler, Y. Wang, B. Misselwitz, Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis, *J Lipid Res* 60 (2019) 1270-1283. 10.1194/jlr.M093229.

ABSTRACT

Chondrocyte oxiaoptophagy mediated by 7 α ,25-DHC-EBI2 axis in IL-1 β -induced arthritis

Jeong-Yeon Seo

Advisor : Prof. Hong Sung Chun, Ph.D.

Department of Integrative Biological Sciences
Graduate School of Chosun University

Oxysterol 7 α ,25-dihydroxycholesterol (7 α ,25-DHC) is synthesized by cytochrome P450 family 7 subfamily B member 1 (CYP7B1) from 25-hydroxycholesterol (25-HC) under inflammatory conditions, associated with the apoptosis of various cell types. In this study, the antagonism of the 7 α ,25-DHC receptor Epstein-Barr virus-induced G-protein-coupled receptor 2 (EBI2) and its mechanism were analyzed in interleukin-1 β (IL-1 β)- or 7 α ,25-DHC-induced chondrocyte oxiaoptophagy.

This study showed that IL-1 β induced the progressive degeneration of articular cartilage though the acceleration of proteoglycan loss in the *ex vivo* organ cultured explant of articular cartilage dissected from rat knee joint. Sequentially, IL-1 β -induced arthritis was mediated by the suppression of extracellular matrix (ECM) component such as aggrecan and type II collagen, the expression and activation of cartilage degrading enzymes such as matrix metalloproteinase -1, -3, and -13, and even the increase of inflammatory mediators including inducible nitric oxide synthase, cyclooxygenase-2, nitric oxide, and prostaglandin E₂ in primary rat chondrocytes. Furthermore, IL-1 β decreased the viability of chondrocytes through apoptosis mediated by the cascade activation of pro-apoptotic caspases, such as caspase-8, -9, and -3. In addition, the expression of autophagy-related biomarkers, such as beclin-1 and Microtubule-associated protein 1A/1B-light chain 3 (LC3), was significantly increased in both chondrocytes and articular cartilage under IL-1 β -induced inflammatory condition. Additionally, IL-1 β did not only increase the expression of oxysterol

syntheses such as CH25H and CYP7B1, but also up-regulate the synthesis of 25-HC in chondrocytes. Hence, these data indicate that IL-1 β -induced arthritis is not only mediated by apoptosis of chondrocytes, but also is accompanied with the synthesis of oxysterols such as 25-HC and 7 α ,25-DHC under inflammatory condition.

Next, the present study demonstrated that both 25-HC and 7 α ,25-DHC induced the caspase dependent apoptosis, the upregulation of ROS production, and the expression of autophagy biomarkers such as beclin-1 and LC3. In addition, both oxysterols induced the progressive degeneration of articular cartilage through the acceleration of proteoglycan loss. Hence, these data indicate that both oxysterols induce the degeneration of articular cartilage through the oxiaoptophagy accompanied with oxidative stress, apoptosis, and autophagy in chondrocytes. Furthermore, the antagonism of EBI2, a receptor activated by 7 α ,25-DHC, did not only counteract the 7 α ,25-DHC-induced cytotoxicity and apoptosis, but also suppress both the production of ROS and the expression of autophagy biomarkers in chondrocytes. Moreover, NIBR189, an EBI2 antagonist, ameliorated the 7 α ,25-DHC-induced proteoglycan depletion in the *ex vivo* organ cultured explants of articular cartilage. These data suggest that antagonism of EBI2 might have an anti-catabolic effect to prevent the progressive degeneration of articular cartilage through the counteraction against to 25-HC-7 α ,25-DHC-induced chondrocyte oxiaoptophagy in the synovial joint under inflammatory conditions.

Hence, it was hypothesized that the inhibition of EBI2 might counteract the IL-1 β -induced arthritis through the suppression of chondrocyte oxiaoptophagy. NIBR189 counteracted significantly against to IL-1 β -induced severe catabolic effects such as the proteoglycan depletion in *ex vivo* organ cultured explants of articular cartilage, the suppression of ECM components, the expression and activation of cartilage degrading enzymes, and the upregulation of inflammatory mediators. Furthermore, NIBR189 did not only ameliorate the IL-1 β -induced cytotoxicity and caspase dependent apoptosis in chondrocytes, but also counteract against to IL-1 β -induced autophagy.

Taken together, these results suggest that antagonism of the 7 α ,25-DHC receptor EBI2 can inhibit 7 α ,25-DHC-induced chondrocyte oxiaoptophagy. Finally, as a result of this study, it is thought that the application of EBI2 inhibition can provide directions for arthritis prevention and arthritis treatment strategies.